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CHAPTER I
INTRODUCTION
Helicobacter pylori 
  H. pylori is a gram-negative, microaerophilic bacterium that selectively colonizes 
the human stomach. It  is one of the most common infections of man and one of the most 
successful pathogens as it infects approximately 50% of the world’s populations (1). H. 
pylori is the main cause of peptic ulceration, gastric lymphoma, and gastric 
adenocarcinoma (2). Importantly, the gastric cancer associated with H. pylori infection is 
the second leading cause of cancer-related death worldwide (3). Consequently, H. pylori 
was the first bacterium to be classified as a class 1 carcinogen in 1994 (4). Despite 
inducing gastritis in all infected individuals, only  a small percentage of individuals 
infected with H. pylori ever develop  peptic ulcer disease or gastric cancer, indicating that 
other factors may be involved (1). Infection with H. pylori occurs worldwide, however, 
developing countries have a higher prevalence than developed countries (5). The 
differences in prevalence have been attributed to the rate at which children acquire the 
infection. The infection persists for the life of the host  despite eliciting a seemingly 
vigorous immune response (6). Understanding the mechanisms by  which H. pylori avoids 
being eliminated by the immune system is clinically relevant because antibiotic-based 
eradication regimens are expensive and not always effective, with success rates that can 
be less than 50% in some regions of the world (7). 
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Discovery of H. pylori and its association with gastric disease
  Spiral-shaped bacteria were reported to colonize the human gastric mucus layer as 
early as 1893 (8); however, it was not until the groundbreaking findings of Barry J. 
Marshall and J. Robin Warren in the 1980’s that  infection with this ‘unknown curved 
bacillus’ was demonstrated to be the causative agent of the majority  of cases of chronic 
gastritis and duodenal ulcers (9). Marshall and Warren were able to demonstrate the 
presence of these spiral-shaped, gram-negative bacteria in patients undergoing endoscopy 
(10); however, further analysis was hampered by the inability to culture the bacteria. 
Interestingly, they found a strong correlation between the presence of the bacteria and 
gastritis and a 100% correlation between presence of the bacteria and duodenal ulcers 
(10). Serendipitously, the investigators were eventually able to culture the organism and 
initially named it Campylobacter pyloridis (11). In the field of gastroenterology, there 
was much skepticism concerning a bacterial cause for gastritis and peptic ulcers, as there 
was a long-standing belief that stress along with certain lifestyle factors were the primary 
cause of duodenal ulcers. In order to prove his hypothesis, Marshall went so far as to 
drink a culture of the bacterium, document the resulting gastritis by endoscopy, and 
eliminate the infection with antibiotic treatment (9). To further test their hypothesis, 
Marshall and Warren undertook a double-blind trial of duodenal ulcer relapse after 
eradication of Campylobacter pyloridis (12). Therein, they  demonstrated that treatment 
with bismuth subcitrate and the antibiotic tinidazole eradicated the infection in the 
majority  of patients. Consequently, elimination of the infection resulted in the healing of 
peptic ulcers. This study, along with many others, provided the convincing evidence 
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necessary  to begin treating patients with antibiotics supplemented with bismuth to 
eliminate H. pylori-induced gastritis and ulcers. Their discovery  of the role of H. pylori in 
gastritis and peptic ulcer disease was so significant that they received the Nobel Prize in 
Medicine in 2005. 
Immunology of H. pylori infection
  Although the bacterium induces a seemingly vigorous chronic adaptive and innate 
immune response, H. pylori and the associated chronic inflammation persists for the life 
of the host and defense mechanisms are not effective in eradicating the organism (6). The 
reasons for the ineffective response are complex; in addition to its own defense factors, 
H. pylori induces multiple events that  result in immune dysregulation (13). Much of the 
experiments delineating these processes have been performed using animal models of H. 
pylori infection. To date, several animal models have been developed using mice, rats, 
monkeys, Mongolian gerbils, guinea pigs, beagle dogs, cats, gnotobiotic piglets, and 
ferrets (14, 15). Most of the work discussed herein will focus on experimental data 
derived from humans, mice, and Mongolian gerbils. The experimental model will be 
noted in the discussions that follow. Below is a summary of recent work on the immune 
response to H. pylori. 
  Adaptive immunity. H. pylori infection of mice induces the infiltration of 
lymphocytes into the stomach of mice 10 d post-inoculation (16). Both T and B cells are 
present in the infected gastric mucosa, with most of the T cells being CD4+ (17, 18). H. 
pylori infection induces the expression of several pro-inflammatory  cytokines, such as 
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IFN-γ, IL-12, IL-17, TNF, and IL-6 (19, 20). However, there is little expression of IL-4 
(21). Furthermore, splenocytes isolated from infected mice also produce more IFN-γ and 
IL-2 than IL-4 and IL-5, suggesting a Th1 response (22). Such a response is similarly 
found in humans (23). Th1 immunity typically develops in response to bacteria that 
reside intracellularly. Because H. pylori is an extracellular bacterium, a Th1 response may 
be unnecessary. However, several studies suggest that the defect in the immune response 
may be that the Th1 response is not vigorous enough (6).
  The infiltration of T cells into the gastric mucosa of infected mice is necessary for 
the onset of gastric inflammation (24). In severe combined immunodeficient mice (SCID, 
mice lacking mature T and B cells), there is minimal inflammation in the stomach (25). 
Furthermore, adoptive transfer of splenocytes from infected immunocompetent mice into 
SCID mice induces more severe gastric inflammation (26). As mentioned above, 
splenocytes stimulated with H. pylori produce high-levels of IFN-γ. Consistent with this 
data, IFN-γ–/– mice have decreased gastritis, providing evidence that Th1 responses are 
associated with increased gastritis (27). 
  In addition to IFN-γ-dominant Th1 responses, there is evidence that Th17 
responses are also important (28, 29). IL-17 levels are increased in infected mice and 
humans and have been linked to chemokine-mediated neutrophil infiltration (16, 30), a 
hallmark of H. pylori infection. Additionally, prophylactic immunization of mice induces 
high-level expression of IL-17 that is associated with enhanced gastritis and decreased 
bacterial colonization (31). These data provide evidence suggesting that a tempered Th17 
response may be responsible for persistent bacterial colonization.
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  The inflammatory response to infection with H. pylori is also affected by the 
infiltration of regulatory T cells (Tregs) expressing CD4, CD25, and Foxp3 (32). Tregs 
can suppress T cell proliferation and cytokine production (33). Furthermore, Tregs 
produce anti-inflammatory cytokines, such as IL-10, which counteract the pro-
inflammatory cytokines produced by Th1-type T cells (33). Additionally, depletion of 
Tregs can reverse these effects in circulating memory  T cells (34). Further evidence has 
accumulated which suggests that Treg induction may be detrimental to host immunity 
against H. pylori. In mice lacking T cells, adoptive transfer of lymphocytes depleted of 
Tregs resulted in a significant reduction in H. pylori colonization and increased gastric 
inflammation as compared to mice receiving non-depleted lymphocytes (34). 
Furthermore, there was enhanced production of IFN-γ. Additionally, depletion of Tregs in 
wild-type (WT) mice also enhanced gastric inflammation, pro-inflammatory cytokine 
production, and decreased bacterial colonization (32). Humans also have enhanced Treg 
infiltration of the stomach during H. pylori infection which may  contribute to bacterial 
persistence (35). However, Tregs may play  an important role in tempering the immune 
response to decrease overall tissue damage caused by the inflammatory response (36). 
  Infection by extracellular bacteria typically induces the production of antibodies. 
These antibodies may  act in several ways in order to lessen the burden of the infection, 
which may  include binding to bacteria and inducing complement activation that can 
result in formation of holes in the bacterial membrane, inactivation of bacterial toxins, 
and induce the phagocytosis of the bacterium (37). H. pylori elicits an antibody  response 
and immunoglobulin deposits have been shown on H. pylori on the gastric surface (38, 
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39). In patients, H. pylori infection induces autoreactive antibody responses due to the 
molecular mimicry between H. pylori proteins and H+K+-ATPase (40). Thus, H. pylori 
infection may contribute to autoimmune gastritis by promoting an immune response 
against self antigens.  Immunization with H. pylori antigens can elicit protective 
immunity  that is not dependent upon B cells (41). In mice with active immunization with 
H. pylori antigens, MHC class II-deficient mice failed to develop protection (42), 
whereas B cell-deficient mice (µMT) were fully protected after immunization (41). Other 
studies have demonstrated that antibody responses are not only dispensable during H. 
pylori infection, but they are detrimental to the elimination of the bacteria. In B cell-
deficient and WT mice infected with H. pylori for 8 and 16 weeks, the B cell-deficient 
mice demonstrated more than a two log order decrease in bacterial colonization as 
compared to the WT mice (41); however, the bacteria were not completely eradicated. 
Furthermore, IgA antibody responses have also been implicated to have a negative effect 
in H. pylori infection (43). One area in humoral immunity that has received attention is 
the development of gastric mucosa-associated lymphoid tissue (MALT) lymphoma which 
arises from B cells. Our laboratory has demonstrated that B cells are protected from 
spontaneous apoptosis and undergo proliferation in response to stimulation with a low 
inoculum of H. pylori (44). 
  Innate immunity. H. pylori causes an inflammatory  reaction with both 
polymorphonuclear and mononuclear cells (45). These cells produce pro-inflammatory 
cytokines and chemokines including IL-1β, IL-6, TNF-α and IL-8 (19, 20). Products of 
H. pylori can also activate immune cells in vitro, and have been detected in the lamina 
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propria (46). H. pylori has been considered noninvasive, but studies have demonstrated 
H. pylori invasion of gastric epithelial cells in vitro (47) and in vivo (48), and into 
microvessels of the lamina propria (49). Importantly, H. pylori has recently been 
demonstrated to be in direct  contact with immune cells of the lamina propria in the 
majority  of both gastritis and gastric cancer cases using transmission electron microscopy 
and immunogold detection (50). Peripheral blood mononuclear cells stimulated with H. 
pylori show larger increases in IL-12 than IL-10 (51). IL-12 drives Th1 lymphokine (IFN-
γ) responses to H. pylori, and bacterial products inhibit  mitogen-activated lymphocyte 
proliferation (52). Gastric epithelial cells act as antigen presenting cells and activate 
CD4+ T cells (53). Upon activation, dendritic cells (DCs) can stimulate either a Th1 or 
Th2/regulatory T cell response (54). DCs activated by  H. pylori undergo maturation (55, 
56), allowing them to elicit a Th1 response in T cells (57), but the IL-12 response may be 
attenuated compared to that observed with other pathogens (58). 
  Recognition of H. pylori. Additionally, the innate immune system plays a vital 
role in the recognition of H. pylori by stimulation and activation of certain pattern-
recognition receptors. These are evolutionarily conserved receptors that are responsible 
for identifying pathogen-associated molecular patterns, which are associated with 
microbial pathogens (59). In H. pylori infection, there is accumulating evidence 
suggesting the importance of toll-like receptors (TLRs) in the recognition of the 
bacterium (60, 61). 
  There are several TLRs that have been discovered which recognize various 
microbial molecular patterns (62). Much of the work to determine the role of TLRs 
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during H. pylori infection has focused upon TLR4, TLR2, and TLR5. The microbial 
patterns that stimulate these receptors are bacterial lipopolysaccharide (LPS), fungal 
mannans, and host heat shock proteins for TLR4, bacterial peptidoglycan, lipoprotein, 
and lipoteichoic acid for TLR2, and bacterial flagellin for TLR5 (63). Stimulation of 
epithelial cells results in upregulation of TLR4, leading to the activation of NF-κB and 
IL-8 production (64). However, others have suggested that  IL-8 expression in epithelial 
cells activated with H. pylori is independent of TLR4 because blocking TLR4 stimulation 
using a monoclonal antibody  does not prevent IL-8 expression (65). Additionally, one 
explanation as to why H. pylori LPS may not be important for H. pylori recognition and 
TLR4 stimulation is because it is an ineffective activator of the immune response 
compared to LPS from other Gram-negative bacteria, due to modifications in the LPS 
lipid A core (66). 
  Epithelial cells in the stomach and intestine also express TLR2 (67). H. pylori 
stimulation of HEK293 cells transfected with TLR2 allowed these cells to respond to the 
bacterium and produce IL-8 (67). However, transfection with TLR4 did not induce IL-8 
production. One of H. pylori’s virulence factors, neutrophil-activating protein, is a known 
TLR2 agonist that stimulates production of oxygen radicals from neutrophils (68, 69). 
Additionally, TLR2 polymorphisms have been associated with gastric cancer (70). 
  TLR5 responds to stimulation with flagellin and may play  an important role in 
recognition of H. pylori because the bacterium is flagellated. TLR5 is present on gastric 
epithelial cells and transfection of HEK293 cells with TLR5 leads to IL-8 production 
upon stimulation with H. pylori (67). However, others suggest that TLR5 may  not be 
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important in recognition of H. pylori because some data suggest that H. pylori flagella 
have low immune-stimulating activity (71). Some have provided evidence suggesting that 
H. pylori flagellin contains specific amino acid substitutions within the TLR5 recognition 
site that prevents its recognition (72). 
Protective immunity against H. pylori
  Several animal models have now provided insight into the failure of the immune 
response to eliminate the infection with H. pylori by demonstrating various mechanisms 
by which bacterial colonization can be decreased or eradicated and eliciting protective 
immunity. Vaccination studies have provided a model to study protective immunity 
against H. pylori because most vaccination protocols against H. pylori are effective in 
either preventing infection with H. pylori or eliminating an established infection (73). 
Initially studies suggested that protective immunity was mediated by antibodies specific 
against H. pylori. However, immunization of mice unable to produce antibodies still 
provided protective immunity (41). 
  Further studies sought to determine which cell types were important for protective 
immunity  during immunization. Mice that are lacking CD8+ T cells still exhibit protective 
immunity  following immunization; however, mice lacking CD4+ T cells do not (42). 
Furthermore, CD4+ T cells isolated from an immunized mouse can provide protective 
immunity  when adoptively-transferred into mice lacking mature T and B cells (74). 
Protective immunity does not occur in mice lacking IL-12 or IFN-γ (17, 27), but does 
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occur in mice lacking IL-4 (75), further suggesting that an enhanced Th1 response is 
needed in order to eliminate the infection. 
  Additionally, mast cells have been reported to play an essential role in protective 
immunity  against H. pylori. Using mast cell-deficient mice (KitW/W-v), one group has 
demonstrated that mast  cells are needed to provide protective immunity  in a vaccination 
model (76). However, this study  has been criticized because the mice used in this study 
have been shown to develop mast cell populations during cutaneous and intestinal 
chronic inflammation. Furthermore, the authors used a mouse model of Helicobacter 
felis, instead of H. pylori. Another group repeated similar experiments using a different 
mast cell-deficient mouse model (KitlSl/Sl-d). They found that protective immunity still 
occurred in these mice (77). However, the authors demonstrated that  mast cells do 
contribute to vaccine-induced immunity, possibly  by contributing to neutrophil 
recruitment and inflammation. 
  Neutrophils have been shown to be important for vaccine-induced immunity. 
Antibody-mediated depletion of neutrophils has been shown to prevent protective 
immunity  against H. pylori (78). IL-10–/– mice, which can spontaneously eliminate H. 
pylori infection, have increased levels of neutrophil infiltration upon infection (79). 
Enhanced neutrophil responses in IL-10–/– mice appears to be related to increased IL-17 
production by these mice (31). Furthermore, antibody-mediated neutralization of IL-17 in 
vaccinated mice that were subsequently  challenged with H. felis resulted in reduced 
infiltration of neutrophils with no reduction in bacterial colonization (80). Additionally, 
depletion of neutrophils in IL-10–/– mice delays clearance of an H. pylori infection (78).
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H. pylori immune evasion strategies
  Of the many bacterial species that have been discovered thus far, very few are 
capable of colonizing human beings. Of those that colonize humans, only a handful will 
actually cause disease. This is due, in part, to the expertise of the human immune system. 
Nevertheless, several bacteria have devised brilliant strategies to bypass critical 
components of our immune system. Included in this group is H. pylori, which may be 
considered the most successful human pathogen due to its ability  to colonize its human 
host for the duration of the host’s life and its remarkable ability  to colonize approximately 
50% of the total world’s population (81). The success of H. pylori is possibly due, in part, 
to the fact  that it has coexisted with humans for a very long time (82). Recent genetic 
studies have indicated that H. pylori spread during human migrations from east Africa 
around 58,000 years ago (83). Consequently, it has been proposed that infection with H. 
pylori may provide a selective evolutionary advantage due to the long-term relationship 
between humans and H. pylori (81, 84). Additionally, only a small percentage of infected 
individuals develop  peptic ulcer disease or gastric adenocarcinoma, and this usually takes 
several decades of infection (1). Due to this long-term cohabitation between humans and 
H. pylori, these bacteria have devised several strategies to avoid being eradicated by  the 
immune response and provides an excellent model of chronic colonization and 
inflammation. 
  A major blockade for bacterial colonization of the stomach is the acidic 
environment. Most bacterial species are killed upon encounter with the low pH levels 
found in the human stomach. However, H. pylori overcomes this obstacle by the 
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production of ammonia, which acts as a buffer to the surrounding acidity (85) (86). The 
production of ammonia is performed  by the H. pylori enzyme urease, which converts 
urea into carbon dioxide and ammonia. Consequently,  mutant strains of H. pylori that 
lacks urease, or the urea transporter, are unable to colonize mice (87, 88). Additionally, 
the bacteria are able to burrow themselves deep into the mucus layer of the stomach, 
directly   above the epithelial cells where the pH is closer to neutral (89). The ability  to 
establish this location is facilitated by H. pylori’s flagella. Similar to urease, flagella are 
also required for bacterial colonization (90). 
  One of H. pylori’s virulence factors, neutrophil-activating protein, induces the 
infiltration and activation of neutrophils and monocytes (69). Upon activation, 
neutrophils produce reactive oxygen species which cause a wide range of damage to 
proteins, DNA, and lipids and are effective at  killing several types of bacteria (91). H. 
pylori is capable of avoiding killing by  reactive oxygen species by expressing enzymes 
that can scavenge reactive oxygen species such as catalase, superoxide dismutase, and an 
NADPH-dependent quinone reductase. These three enzymes scavenge hydrogen 
peroxide, superoxide, and NADPH respectively. Depletion of NADPH is important for 
bacterial survival because it is needed by neutrophils in order to produce superoxide. It 
has been suggested that the purpose of neutrophil-activating protein is to induce 
inflammation in order to obtain nutrients from the inflamed tissue (92). 
  H. pylori also induces the activation of macrophages to produce the enzyme 
inducible nitric oxide (NO) synthase (iNOS), which metabolizes L-arginine into NO that 
can kill H. pylori (93). The importance of iNOS in the innate immune response is 
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demonstrated by the increased susceptibility  to various bacterial infections in mice 
deficient of iNOS (94). iNOS produces NO in copious amounts that, similar to reactive 
oxygen species, is antimicrobial and can cause damage to proteins and DNA (95). To 
avoid killing by NO, H. pylori expresses the enzyme arginase which effectively steals the 
substrate L-arginine away from macrophage iNOS (96). Consequently, a mutant strain of 
H. pylori that is deficient for arginase is effectively killed by macrophages in a coculture 
system, whereas WT H. pylori is not (96). Additionally, NO can react with superoxide to 
form peroxynitrite, a very volatile, cytotoxic, and mutagenic reactive nitrogen species 
that can kill bacteria (95). H. pylori possesses a peroxiredoxin, a homolog of Salmonella 
typhimurium’s alkylhydroperoxide reductase subunit C, that can effectively detoxify 
peroxynitrite and evade being killed by this reactive nitrogen species (97).
  Intriguingly, H. pylori arginase has also been shown to be detrimental to T cell 
responses. It has been demonstrated that L-arginine is needed for the re-expression of the 
CD3ζ chain of the T cell receptor (98). Consequently, H. pylori arginase steals away  the 
L-arginine from T cells, thereby inhibiting the re-expression of the CD3ζ chain  and 
inhibiting T cell proliferation (99).
  Furthermore, it has been demonstrated that H. pylori upregulates in macrophages 
the enzyme ornithine decarboxylase (ODC) that leads to the production of polyamines 
(100). The polyamine spermine has been shown to inhibit  macrophage NO production by 
blocking L-arginine uptake (93). The L-arginine transporter cationic amino acid 
transporter 2 (CAT2) is necessary for NO production by iNOS in macrophages (101). By 
blocking L-arginine uptake in macrophages, spermine synthesis by ODC contributes to 
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bacterial survival (102). Importantly, chemical inhibition of ODC during H. pylori 
infection led to enhanced NO production by macrophages and a significant decrease in 
bacterial colonization after 4 months (102).  
  In addition to scavenging reactive nitrogen and oxygen species, H. pylori has also 
adopted mechanisms to avoid killing by  phagocytosis. It  has been elegantly demonstrated 
that cholesterol promotes the phagocytosis of H. pylori (103). Interestingly, H. pylori 
expresses an enzyme, cholesterol-α-glucosyltransferase, that glucosylates cholesterol and 
inhibits phagocytosis by  macrophages (103). The mechanism by which glucosylated 
cholesterol inhibits phagocytosis is unclear. Additionally, it has been demonstrated that a 
cholesterol-rich diet during bacterial challenge leads to a T cell-dependent reduction of 
the H. pylori burden in the stomach (103). Consequently, glucosylation of cholesterol 
inhibits T cell responses in an antigen-specific manner (103).  However, if cholesterol is 
present and H. pylori is phagocytosed, the bacterium possesses additional strategies to 
avoid being killed by  phagocytosis. Upon being phagocytosed, H. pylori delays the 
maturation of phagosomes and causes the formation of large phagosomal structures called 
megasomes (104). By delaying phagosome maturation and preventing its death, the 
bacterium could potentially  induce apoptosis in these cells and possibly  escape out of the 
cells. It has been reported that inhibition of phagosome maturation only occurs with 
virulent, type I strains of H. pylori (strains that express both CagA and VacA) (104, 105); 
however, this has been disputed (106). 
  Another H. pylori virulence factor, VacA, has been shown to have multiple roles 
in the evasion of host immune responses. VacA has been reported to interfere with the 
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presentation of antigens by B cells (107). Antigen presentation by B cells to T cells was 
defective when B cells were exposed to VacA (107). Additionally, VacA is detrimental to 
proper T cell function. It has been reported that VacA interferes with the activity  of 
nuclear factor of activated T cells (NFAT), which results in inhibition of IL-2 expression, 
decreased T cell proliferation, and cell cycle arrest (108). 
Role of iNOS
  Since the discovery of NO as a molecule with an extensive array  of biological 
functions and the identification of iNOS that  is responsible for high-output  NO 
production, there has been intense interest in iNOS as a regulator of mucosal 
inflammation and injury. Studies in the intestine have shown inconsistent results (109). In 
the case of iNOS in H. pylori infection, our laboratory  reported that  iNOS is induced by 
H. pylori in vitro in macrophages (Fig. 1) (110) and in vivo in human gastritis tissues 
(111), and that soluble factors released by H. pylori can induce macrophage iNOS in the 
absence of bacterial contact with the cells (112). The generation of NO in response to H. 
pylori infection has an important role in host defense. Our laboratory reported that 
macrophages kill H. pylori by an NO-dependent mechanism (93, 96) and that the 
bacterium possesses an arginase enzyme that facilitates survival by competing with iNOS 
for the same substrate, L-arginine (96). Our laboratory has also shown that activation of 
ODC by H. pylori results in loss of innate immunity  via spermine-mediated inhibition of 
iNOS at the level of protein translation (93). The mechanism by which this occurs is by 
the inhibition of L-arginine uptake by CAT2 (102), as has been discussed previously. We 
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recently  reported that the generation of NO by macrophages in response to H. pylori is 
entirely  dependent on the availability  of L-arginine and that this results in increased 
expression of iNOS protein, without altering the induction of mRNA expression (113). 
Specifically, we found that the addition of increasing levels of extracellular L-arginine 
results in a proportionate increase in NO production even at concentrations well above 
the circulating levels of L-arginine in humans and mice of 0.1 mM (114, 115), and above 
the Km of the iNOS enzyme for L-arginine, which is in the range of 10 µM (116, 117). In 
order for macrophages to produce bactericidal amounts of NO when cocultured with H. 
pylori in our model system, concentrations of L-arginine in the medium that exceeded 0.1 
mM were needed (113).
Importance of arginase
  Many have concluded that it  is difficult to predict the effects of NO in the milieu 
of mucosal inflammation. This may be due in part to arginase. Arginase converts L-
arginine to L-ornithine (Fig. 1). Ornithine is acted upon by ODC to form polyamines. 
Thus, arginase is the endogenous competitive inhibitor for iNOS. Two forms of arginase 
have been purified and cloned. Arginase I (Arg1) is cytosolic in location, and abundant in 
liver; it has been referred to as “hepatic” arginase (118). Arginase II (Arg2) is 
mitochondrially-associated, present in most tissues, and referred to as the “extrahepatic” 
form (119). The Km values for L-arginine of arginase I and II are ~10 mM  and are much 
higher than the Km value for iNOS, which is ~5 µM. However, the Vmax of arginase I and 
II are 103-104 times higher than that of iNOS in activated macrophages. Therefore, the 
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Vmax/Km values are similar and these enzymes are expected to compete for L-Arg in the 
cells (120). Our laboratory has shown that Arg1 is the predominant  form upregulated in 
colitis models, where it has a beneficial role (121), while Arg2 is upregulated in H. pylori 
gastritis (122), and induction of Arg2 in H. pylori-stimulated macrophages results in 
apoptosis (122). Induction of arginase activity by pathogens has been reported to 
modulate macrophage NO production in the case of both Arg1 (123-126), and Arg2 (127, 
128), which can restrict effective immunity.  These effects have been attributed to 
substrate competition, but alterations in iNOS expression have not been studied. 
The downstream effectors of arginase activity: polyamines
  The mammalian polyamines are putrescine, spermidine, and spermine (129). 
ODC forms putrescine from L-ornithine. Spermidine is formed from putrescine by 
spermidine synthase and spermine is formed by  spermine synthase (Fig. 1). Polyamines 
have been implicated in carcinogenesis (130). Spermine can inhibit LPS-stimulated pro-
inflammatory cytokine production in monocytes, macrophages, and lymphocytes (131, 
132). Injection of spermine inhibits acute footpad inflammation (131). While polyamines 
may be anti-inflammatory  in acute inflammation, in chronic inflammation, as in H. pylori 
infection, suppression of immune responses could contribute to persistence and 
progression of the disease. Polyamine levels have been shown to be increased in the 
gastric mucosa in human H. pylori infection (133). 
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ODC and polyamine oxidation
  Although ODC is the rate-limiting step  in polyamine synthesis, availability  of L-
ornithine substrate can become a factor, as with our observation that inhibition of either 
arginase or ODC blocked macrophage apoptosis (Fig. 1) (122). Regulation of polyamine 
homeostasis occurs through metabolism and efflux of intracellular polyamines. In one 
pathway, spermine or spermidine are acetylated by spermidine/spermine N1-
acetyltransferase, and this allows efflux of polyamines from cells, which occurs in the 
acetylated form (134). Our collaborator, Robert Casero, and others have identified an 
enzyme, polyamine oxidase 1, later renamed spermine oxidase (SMO), which is inducible 
and selectively uses spermine as substrate. Catabolism of polyamines by SMO produces 
H2O2 , which can result in induction of apoptosis (135). Oxidation of polyamines has 
been shown to induce mitochondrial uncoupling and release of cytochrome c (136), 
which is known to activate caspases, and thus apoptosis. Our laboratory has implicated 
this pathway in H. pylori-induced apoptosis in macrophages and epithelial cells (137).
Apoptosis in H. pylori gastritis
  Programmed cell death (apoptosis) has been implicated in the pathogenesis of H. 
pylori-induced inflammation. Induction of apoptosis in gastric epithelial cells has been 
well-demonstrated in vitro (138) and in vivo (139). H. pylori causes lymphocyte 
apoptosis in vitro, which has been postulated to contribute to the ability  of H. pylori to 
evade the immune response (140). Studies from our laboratory have demonstrated that H. 
pylori also induces macrophage apoptosis and that this occurs by the activation of Arg2, 
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ODC, and SMO (Fig. 1) (93, 122, 137). We contend that this apoptosis contributes to the 
persistence of H. pylori by attenuating innate immunity. It  has been demonstrated that 
macrophages are important in the immune response to H. pylori and their removal results 
in increased bacterial colonization (141). Furthermore, macrophages have been shown to 
release the pro-inflammatory  cytokine IL-1ß during apoptosis in other models (142, 143). 
This may contribute to the severity of gastritis in H. pylori infection.
Significance, summary, and dissertation goals
  The demonstration that H. pylori is the primary cause of chronic gastritis and 
peptic ulcer disease in humans (10) was one of the major medical discoveries of the 20th 
century and merited the Nobel Prize in Medicine in 2005. The identification of H. pylori 
as the etiological agent for gastric adenocarcinoma and mucosa-associated lymphoid 
tissue (MALT) lymphoma further emphasizes the clinical relevance of this pathogen. 
Although these epidemiological associations are established, strategies for disease risk 
assessment are inadequate. H. pylori infection is characterized by the presence of chronic 
active gastritis, i.e. both mononuclear cell (lymphocytic) and polymorphonuclear cell 
(neutrophilic) infiltration, and persistence of the bacterium despite many years of 
infection. Thus, the immune response is ineffective. The focus in our laboratory  has been 
to provide insight into this failure to eradicate the organism and the causes of the 
inflammation. Our data support the concept  that there are fundamental defects in the host 
response that can be attributed to alterations of L-Arg metabolism (Fig. 1). We propose 
that diversion of L-Arg to the arginase pathway  is detrimental in the immune response 
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against H. pylori. Using in vitro and in vivo models we seek to develop clues into the 
regulation of cellular function in the setting of H. pylori infection that may prove 
fundamentally important in establishing how the bacterium evades the immune response. 
Knowledge gained will have relevance to other gastrointestinal inflammatory conditions, 
infections, and neoplasias. 
  In Chapter II, we examined the importance of H. pylori-induced expression of 
macrophage Arg2 in vitro and determined its effects on iNOS activity. We demonstrated 
for the first time that upregulation of macrophage Arg2 by  an extracellular bacterium 
results in diminished NO-dependent killing. Moreover, our studies demonstrating that 
inhibition of macrophage arginase results in enhanced iNOS-derived NO production in 
response to H. pylori in vivo indicate that such a strategy could enhance the ability  of the 
immune system to control or eliminate H. pylori infection.
  In Chapter III, we examined the importance of H. pylori-induced expression of 
Arg2 in vivo in a chronic infection model. We demonstrated that H. pylori upregulates 
Arg2 in the gastric mucosa that localizes to F4/80+ macrophages, thereby restricting 
iNOS protein levels and NO production, and enhancing macrophage apoptosis. These 
data suggest  that Arg2 induction contributes to the defective immune response in WT 
mice. 
  In summary, our data indicate that  induction of Arg2 by  H. pylori is a mechanism 
by which the pathogen escapes the host  innate immune response and contributes to the 
immunopathogenesis of the infection. Because we have reported that Arg2 is upregulated 
in H. pylori gastritis tissues from human subjects (122), insights into the importance of 
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Arg2 could be gained from molecular epidemiology studies of Arg2 levels in human 
subject groups from populations with high prevalence rates of H. pylori infection.
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FIGURE 1. L-arginine metabolism in macrophages stimulated with H. pylori. This 
figure demonstrates the enzymes that are upregulated in macrophages stimulated with H. 
pylori. The figure was adapted from Wilson and Crabtree, Gastroenterology 2007 (6). 
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CHAPTER II
ARGINASE II RESTRICTS HOST DEFENSE TO HELICOBACTER PYLORI BY 
ATTENUATING INDUCIBLE NITRIC OXIDE SYNTHASE TRANSLATION IN 
MACROPHAGES
Summary
  Helicobacter pylori infection of the stomach causes peptic ulcer disease and 
gastric cancer. Despite eliciting a vigorous immune response, the bacterium persists for 
the life of the host. An important antimicrobial mechanism is the production of NO 
derived from iNOS. We have reported that macrophages can kill H. pylori in vitro by an 
NO-dependent mechanism, but supraphysiologic levels of the iNOS substrate L-arginine 
are required. Because H. pylori induces arginase activity  in macrophages, we determined 
if this restricts NO generation by reducing L-arginine availability. Inhibition of arginase 
with S-(2-boronoethyl)-L-cysteine (BEC) significantly enhanced NO generation in H. 
pylori-stimulated RAW 264.7 macrophages by enhancing iNOS protein translation, but 
not iNOS mRNA levels. This effect resulted in increased killing of H. pylori that was 
attenuated with an NO scavenger. In contrast, inhibition of arginase in macrophages 
activated by the colitis-inducing bacterium Citrobacter rodentium increased NO without 
affecting iNOS levels. H. pylori upregulated levels of Arg2 mRNA and protein, which 
localized to mitochondria, while Arg1 was not induced. Increased iNOS protein and NO 
levels were also demonstrated by siRNA knockdown of Arg2 and in peritoneal 
macrophages from C57BL/6 Arg2–/– mice. In H. pylori-infected mice, treatment with 
BEC or deletion of Arg2 increased iNOS protein levels and NO generation in gastric 
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macrophages, but treatment of Arg2–/– mice with BEC had no additional effect. These 
studies implicate Arg2 in the immune evasion of H. pylori by causing intracellular 
depletion of L-arginine, and thus reduction of NO-dependent bactericidal activity.
Introduction
 Helicobacter pylori is a microaerophilic, gram-negative bacterium that selectively 
colonizes the human stomach. It is one of the most successful human pathogens, since it 
infects half of the world's population (6). All infected individuals exhibit chronic active 
gastritis and a substantial proportion develop  peptic ulcer disease or gastric 
adenocarcinoma. Importantly, gastric cancer is the second leading cause of cancer deaths 
worldwide (3). The infection is usually acquired in childhood and persists for the life of 
the host despite eliciting a vigorous innate and adaptive immune response (6). This raises 
the question as to how H. pylori is consistently  able to evade this cellular and humoral 
immune response. H. pylori has generally been considered to be a non-invasive pathogen 
because it resides in the mucus layer of the stomach in contact with the epithelium. 
However, multiple reports have demonstrated that H. pylori can invade the mucosa, with 
elegant studies depicting the organism in direct  contact with lamina propria immune cells 
(49, 50, 148). These findings strongly suggest that the failure of the immune response 
could be directly related to the inability of effector cells to kill the organism when given 
the opportunity to do so.
 One primordial mechanism for antimicrobial host defense is the generation of 
high levels of NO derived from the enzyme iNOS (149). Our laboratory and others have 
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demonstrated that H. pylori induces the expression and activity  of iNOS in macrophages 
both in vivo (111, 150) and in vitro (93, 96, 110, 112, 113, 122). Further, we have reported 
that macrophages cocultured with H. pylori have the ability to kill the bacterium by an 
NO-dependent mechanism (93, 96, 113). However, this killing is incomplete in vitro, and 
moreover, there is clearly a failure of this mechanism in vivo despite the expression of 
iNOS in the infected mucosa. Recently, it  has been emphasized that other components of 
the innate immune response that orchestrate the cellular immunity to H. pylori are 
attenuated; for example, inadequate dendritic cell activation (151) and downregulatory 
effects of regulatory T cells (32) have been directly  implicated in the persistence of the 
organism. Thus, while the Th1 response to H. pylori has been well documented, adoptive 
transfer experiments have suggested that the cellular immune response is not vigorous 
enough to lead to clearance of the infection (24, 27).
 This reasoning has led our laboratory to consider the possibility  that the iNOS-
mediated host defense to H. pylori is suboptimal. We recently reported that the generation 
of NO by macrophages in response to H. pylori is entirely  dependent  on the availability 
of L-arginine and that this results in increased expression of iNOS protein, without 
altering the induction of mRNA expression (113). Specifically, we found that the addition 
of increasing levels of extracellular L-arginine results in a proportionate increase in NO 
production even at concentrations well above the circulating levels in humans and mice 
of 0.1 mM (114, 115), and above the Km of the iNOS enzyme for L-arginine, which is in 
the range of 10 µM (116, 117). In order for macrophages to produce bactericidal amounts 
of NO when cocultured with H. pylori in our model system, concentrations of L-arginine 
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in the medium that exceeded 0.1 mM were needed (113). 
 Arginase enzymes are the endogenous antagonists to iNOS, since they compete 
for the same substrate by  metabolizing L-arginine into urea and L-ornithine (152, 153). 
The latter is metabolized by ornithine decarboxylase (ODC) to produce the polyamines 
putrescine, spermidine, and spermine (154). There are two isoforms of arginase: Arg1 is 
ubiquitous, but is especially  abundant in liver, and Arg2 is abundant in kidney and 
possesses a mitochondrial localization sequence (155-157). We have reported that Arg2, 
but not Arg1, is upregulated in H. pylori-stimulated macrophages (122). Induction of 
arginase activity by pathogens has been reported to modulate macrophage NO production 
in the case of both Arg1 (123, 125, 126, 158), and Arg2 (127, 128), which can restrict 
effective immunity.  These effects have been attributed to substrate competition, but 
alterations in iNOS expression have not been studied. 
 We hypothesized that Arg2 expression can restrict NO-mediated defense against 
H. pylori by  limiting L-arginine availability, and that this may explain the large amounts 
of L-arginine that are required for iNOS synthesis. We now report that H. pylori-
stimulated NO production is attenuated by Arg2 activity  in vitro and in vivo, and that this 
occurs by limiting iNOS protein expression due to an effect on iNOS translation. 
Inhibition of arginase enhanced killing of H. pylori by macrophages. Moreover, we show 
that in H. pylori-infected mice treated with an arginase inhibitor there was markedly 
increased iNOS protein expression and NO production in gastric macrophages. To our 
knowledge, this is the first report that an extracellular bacterium can manipulate host  L-
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arginine metabolism and iNOS protein synthesis by an Arg2-dependent mechanism, 
thereby restricting NO production and bacterial killing. 
Experimental procedures
 Reagents: All reagents used for cell culture and RNA extraction were from 
Invitrogen (Carlsbad, CA). Real-time PCR reagents were from Bio-Rad (Hercules, CA). 
S-(2-boronoethyl)-L-cysteine (BEC), a slow-binding competitive inhibitor of arginase 
(159, 160), was synthesized by J.-L.B (161). 2-(4-carboxyphenyl)-4,4,5,5,-
tetramethylimidazole-1-oxyl-3-oxide (cPTIO) was from Cayman Chemical (Ann Arbor, 
MI). siRNA to ODC and Arg2 were from Ambion (Austin, TX). All other chemicals were 
from Sigma (St. Louis, MO). 
 Bacteria, cells, and culture conditions: H. pylori SS1 was grown and used as 
described (110, 137) and multiplicity of infection (MOI) was defined as the ratio of 
bacteria to eukaryotic cells. C. rodentium was grown and used as described previously 
(121, 162). Macrophages were activated with either live bacteria or lysates prepared with 
a French press (113), and MOIs were determined in lysates as described (110). For 
bactericidal studies, live H. pylori was separated from macrophages by filter supports 
(113). When live bacteria were added, medium without antibiotics was used (93, 96, 
113). Bacterial killing was determined by serial dilution and culture after 24 h of 
coculture, and colony growth was compared between samples cocultured with or without 
macrophages. The murine macrophage cell line RAW 264.7 was maintained in complete 
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DMEM (113). For experiments, medium was changed to L-arginine-free, serum-free 
DMEM supplemented with 0.3% bovine serum albumin as described (113). This was 
followed by addition of desired concentrations of L-arginine (113). 
 Mice: All animal experiments were approved by the Vanderbilt University Animal 
Care and Use Committee. C57BL/6 WT mice were obtained from The Jackson 
Laboratory (Bar Harbor, ME). C57BL/6 Arg2–/– mice were a gift from Brendan Lee 
(Baylor College of Medicine) and were bred at the Nashville Veterans Affairs Medical 
Center. Male mice were used at 8 weeks of age. Peritoneal macrophages were isolated as 
described (93) and used in L-arginine-free, serum-free DMEM. In addition, mice were 
gavaged with 5 × 108 H. pylori SS1 in 100 µl of Brucella broth, or broth alone. In some 
studies, mice were treated with 0.1% (w/v) BEC in the drinking water (121), starting one 
day pre-infection, and continuing for a total of 3 days. Mice were sacrificed 2 days post-
inoculation, and stomachs were excised and used for isolation of gastric macrophages, 
which was performed as described (113). 
 Measurement of NO: The concentration of the oxidized metabolite of NO, nitrite 
(NO2–), was assessed by the Griess reaction (93, 96, 112, 113, 122). 
 Real-time PCR: Primers for iNOS, Arg1, and β-actin were used as described (113, 
122). For Arg2, we used primers that generated a 234-bp product as follows: sense, 5'-
GGATCCAGAAGGTGATGGAA-3' and antisense, 5'-
28
AFAGCTGACAGCAACCCTGT-3'. mRNA was extracted and cDNA was synthesized as 
described (113), and 2 µl were used for real-time PCR for iNOS, Arg1, Arg2, and β-actin 
with the iQ SYBR green Supermix (Bio-Rad). The thermal cycling conditions and the 
method used to calculate relative expression were as described (113).
 Immunoblot analysis: RAW 264.7 cells were treated with H. pylori lysates for 
various time points as indicated in each of the figures. Macrophages were lysed and 
Western blotting for iNOS and β-actin was performed as described (113). For Arg2 
detection, we used a goat polyclonal antibody (L-20) generated against murine Arg2 from 
Santa Cruz Biotechnology (Santa Cruz, CA) at a dilution of 1:500. For Arg1 detection, a 
mouse polyclonal antibody generated against human Arg1 (BD Transduction 
Laboratories, San Jose, CA) was used at a dilution of 1:2000. 
 Detection of iNOS protein by flow cytometry: After stimulation, cells were 
washed, fixed, permeabilized, and stained with anti-iNOS antibody, and flow cytometry 
was performed as described (113). 
 Translation analysis for iNOS: After stimulation of RAW 264.7 macrophages 
with or without H. pylori lysates in the presence and absence of BEC, proteins were 
metabolically labeled with 35S-methionine and analyzed for iNOS translation (93, 113).
 Transient transfection of siRNA in macrophages: ODC siRNA transfection was 
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performed as described (93). For Arg2 knockdown, we used siRNA duplex targeting 
nucleotides 1168–1186 as follows: sense, 5'-GGCAUUCGAAGGGACAGAUtt-3'; 
antisense, 5'-AUCUGUCCCUUCGAAUGCCtt-3'. Scrambled siRNA and conditions for 
transfection and activation were as described (93, 137). 
 Arginase activity in cytosolic and mitochondrial fractions: RAW 264.7 cells were 
lysed and fractionated using the Cytosolic/Mitochondrial Fractionation Kit from 
Calbiochem (La Jolla, CA), according to the manufacturer’s instructions. Proteins from 
both fractions were incubated with 0.1 µM L-guanido-14C-Arg (NEN, Boston, MA) for 
24 h at 37°C, and arginase activity was assayed as described (163). 
 Immunofluorescence staining for Arg2 and mitochondria: RAW 264.7 cells (1 x 
104) were plated in 4-well chamber glass slides. After treatments, MitoTracker Red 
(Invitrogen) was added to the cell cultures at a concentration of 100 nM for 30 min. Cells 
were washed with PBS and fixed in 3.7% formaldehyde. Cells were then permeabilized 
in 100% chilled methanol, washed, and blocked with Background Sniper (Biocare 
Medical, Concord, CA) for 1 h at room temperature. Cells were incubated at room 
temperature for 1 h with primary antibody to Arg2 (1:200 dilution; Santa Cruz 
Biotechnology, Inc., Santa Cruz CA), followed by incubation with FITC-labeled donkey 
anti-goat secondary antibody (1:1000 dilution) for 45 min at room temperature. Cells 
were counterstained with 4',6-diamidino-2-phenylindole (DAPI) for nuclear staining. 
Slides were dried, mounted, and visualized as described (162).
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 Analysis of NO production and iNOS protein expression in gastric macrophages: 
Isolated gastric macrophages were plated in 96-well plates. NO2– concentration was 
assayed by the Griess reaction and iNOS protein assessed by flow cytometry as described 
(113).
 Statistical Analysis: Quantitative data are expressed as means ± SEM. For 
comparisons between multiple groups ANOVA followed by the Student-Newman-Keuls 
multiple comparisons test was used, and for single comparisons between two groups the 
Student’s t test was used. Prism 5.0 (GraphPad Software, Inc., La Jolla, CA) was used for 
all analyses.
Results
Inhibition of arginase enhances H. pylori-induced NO production by macrophages via 
enhancement of iNOS translation
 We sought to determine if arginase expression and activity in macrophages impairs 
the host  response to H. pylori by reducing iNOS-derived NO production. Lysates of H. 
pylori were used for these studies, because we have reported that H. pylori itself 
possesses an arginase enzyme that can compete with host cells for L-arginine utilization 
(96), but this enzyme is inactive in lysates (112, 122). Because we have previously 
reported that NO production increases in an L-arginine-dependent manner (113), we 
studied the effect of arginase inhibition over broad concentrations of L-arginine from 0 - 
1.6 mM (Fig. 2A). In the presence of BEC, a specific inhibitor of arginase that does not 
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directly  affect iNOS expression or activity (160, 164), we detected a significant increase 
in NO production, measured as the concentration of the stable metabolite, NO2–, at all 
concentrations of L-arginine between 0.1 and 1.6 mM, but not in the absence of L-
arginine (Fig. 2A). It  should be noted that concentrations of BEC from 30 to 150 µM 
were tested in this system, and the peak effect on NO production occurred at 90 µM  with 
no detectable cytotoxicity  (data not shown); thus the 90 µM dose was used for the 
remainder of the experiments.
 Arginase inhibition had no effect on H. pylori-stimulated iNOS mRNA expression, 
and increasing L-arginine concentration did not increase iNOS mRNA expression (Fig. 
2B). In contrast, iNOS protein expression increased with the addition of L-arginine, and 
these levels were markedly increased with inhibition of arginase at each level of L-
arginine tested (Fig. 2C). Quantification of iNOS protein levels by densitometry revealed 
increases in iNOS protein levels in the presence of BEC (Fig. 2D). Furthermore, we 
examined the effect of arginase inhibition at time points from 6 to 24 h post-stimulation, 
and found that NO production (Fig. 2E) and iNOS protein levels (Figs. 2F and G) were 
both significantly increased at 18 h and 24 h in the presence of BEC. Additionally, at  12 h 
post-stimulation there was an increase in iNOS protein in the BEC-treated cells that was 
not present in the cells treated with H. pylori alone. Taken together, these data show that 
there is a similar degree of increase in steady-state iNOS protein levels at 12 - 24 h with 
BEC treatment.
 Because we have reported that increased extracellular L-arginine availability 
augments iNOS translation (113), we sought to determine if reduced competition for 
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intracellular L-arginine by experimental inhibition of arginase also enhances iNOS 
translation. When lysates from H. pylori-stimulated cells were immunoprecipitated with 
antibody to iNOS, and 35S-methionine incorporation measured, there was increased iNOS 
translation in the presence of BEC when assessed by both SDS-PAGE (Fig. 2H) and 
quantification of radiolabeled counts (Fig. 2I).
 Because we have reported that knockdown of ODC increased NO production in H. 
pylori-stimulated macrophages by blocking spermine synthesis (93), we compared this 
effect to that of BEC (Fig. 3). Knockdown of ODC or inhibition of arginase resulted in an 
identical increase in NO production (Fig. 3A) with H. pylori stimulation. There was an 
additive effect with both treatments, such that there was a significant potentiation of NO 
production (Fig. 3A). When assessed by Western blot analysis, each treatment caused an 
increase in H. pylori-induced iNOS protein expression, but when added together there 
was not a further increase in iNOS levels (Fig. 3B). 
H. pylori induces macrophage Arg2 that is localized to the mitochondria
 Because we found that inhibition of arginase had a significant effect on iNOS and 
NO production, we explored the effect of H. pylori on the induction of arginase isoforms 
in more depth. RAW 264.7 macrophages were stimulated with H. pylori for 6 h, the time 
point at which we have demonstrated peak mRNA expression responses to H. pylori 
(100, 110, 113, 122), and Arg1 and Arg2 mRNA levels were quantified by real-time PCR 
(Fig. 4A). Arg2 mRNA levels were increased with H. pylori stimulation by  4–fold in the 
presence of L-arginine (from 0.1 – 1.6 mM) and BEC had no effect on this induction 
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FIGURE 2. Arginase inhibition enhances H. pylori-stimulated macrophage NO 
production and iNOS protein expression by  enhancing iNOS translation. 1 × 106 RAW 
264.7 macrophages grown in 1 ml of medium were stimulated with H. pylori (HP) lysates 
at an MOI of 100. Experiments were conducted in arginine- and serum-free DMEM  to 
which known concentrations of L-arginine were added. A, Cells were stimulated with H. 
pylori lysates for 24 h in the presence or absence of the arginase inhibitor BEC (90 µM). 
NO was measured as NO2– in the supernatant. Data are the mean ± SEM of thirteen 
separate experiments. *, p < 0.05, **, p < 0.01, *** p < 0.001 comparing – BEC (medium 
alone) to + BEC at the same concentration of L-arginine. B, iNOS mRNA levels were 
assessed after 6 h by real-time PCR. Data were standardized to β-actin and presented as 
fold increase vs. uninfected control at the 0.4 mM  concentration of L-arginine. Data are 
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the mean ± SEM for three separate experiments. C, Western blotting was performed after 
24 h for iNOS and β-actin, with 30 µg of protein loaded per lane. A representative 
Western blot is shown; similar results were observed in five experiments. Samples from 
cells treated with or without BEC were run on separate gels and the blots were then 
incubated together in the same container with the same antibody and exposed together on 
the same autoradiograph film. D, Densitometry from Western blotting for iNOS. Data 
were normalized to β-actin. Data are the mean ± SEM  for five separate Western blots. *, 
p < 0.05, ***, p < 0.001 comparing – BEC to + BEC at  the same concentration of L-
arginine. E, NO production was measured at various time points from RAW 264.7 cells 
stimulated with H. pylori at an MOI of 100. Data are the mean ± SEM of three 
experiments. ***, p < 0.001 comparing – BEC to + BEC at the same time point. F, 
Densitometry from Western blotting for iNOS protein levels at various time points. Data 
were normalized to β-Actin. Data are the mean ± SEM of three experiments. *, p < 0.05, 
***, p < 0.001 comparing – BEC to + BEC at the same time point.  G, Representative 
Western blot for iNOS at various time points in the presence or absence of BEC. H, iNOS 
translation was measured by  stimulating cells with H. pylori for 18 h and adding 35S-
methionine. After 4 h, iNOS protein was immunoprecipitated and resolved by SDS-
PAGE and phosphorimaged. I, 35S-methionine incorporation in immunoprecipitates was 
determined by scintillation counting. Data are the mean ± SEM  of four separate 
experiments. *, p < 0.05, ***, p < 0.001 compared to controls without BEC. §§, p < 0.01 
compared to HP-stimulated cells treated with BEC.
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FIGURE 3. ODC knockdown and arginase inhibition have an additive effect on H. 
pylori-stimulated NO production in macrophages. RAW 264.7 cells were treated with 
ODC siRNA or scrambled control (Scr) siRNA and stimulated with H. pylori lysates in 
the presence or absence of BEC (90 µM). A, Effect of ODC siRNA and BEC on NO2– 
levels, at  various concentrations of L-arginine. Data are the mean ± SEM of three 
separate experiments. *, p < 0.05, **, p < 0.01, and ***, p < 0.001 compared to Scr 
siRNA at the same concentration of L-arginine. #, p < 0.05, ##, p < 0.01, comparing ODC 
siRNA + BEC to Scr siRNA + BEC at the same concentration of L-arginine. B, Western 
blot analysis for iNOS and β-actin. Experiments were conducted at 0.4 mM  L-arginine. 
Results are representative of three separate experiments.
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(Fig. 4A). It  should be noted that there were higher levels of Arg2 mRNA in the absence 
of L-arginine, similar to the effect  for iNOS (Fig. 2B), which is likely due to cellular 
stress from L-arginine depletion as we have described (113). We confirmed that Arg1 
mRNA levels are not upregulated with H. pylori stimulation, and that BEC did not affect 
Arg1 levels (Fig. 4B). 
When Arg2 protein levels were assessed, there was a significant increase with H. 
pylori stimulation in the presence of L-arginine. This did not change with increasing L-
arginine levels above 0.1 mM, and BEC had no effect on stimulated Arg2 levels (Fig. 
4C). When cells were depleted of L-arginine, there was no detectable Arg2 protein 
expression with H. pylori stimulation despite increased Arg2 mRNA levels. This is 
consistent with our previous findings that a physiologic level of L-arginine (0.1 mM) is 
required for global protein translation to occur in macrophages (113). 
Arg2 has a leader sequence that can target it to mitochondria (165). We therefore 
determined the subcellular localization of Arg2 in macrophages under conditions of H. 
pylori stimulation. When arginase activity was compared in cytosolic and mitochondrial 
fractions, there was a significant increase only in the mitochondrial fraction after H. 
pylori stimulation (Fig. 4D). Consistent with this, H. pylori induced a marked increase in 
Arg2 staining by  immunofluorescence detection that colocalized with mitochondria (Fig. 
4E).
37
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FIGURE 4. Arg2 is upregulated by H. pylori stimulation in macrophages and localizes to 
the mitochondria. A, Arg1 and B, Arg2 mRNA expression was assessed by real-time PCR. 
Data were standardized to β-actin and presented as fold increase vs. uninfected control 
cells at the 0.4 mM concentration of L-arginine. Data are the mean ± SEM for three 
separate experiments. C, Representative Western blot  is shown for Arg2 and β-actin in the 
presence or absence of BEC (90 µM) with cells harvested at 24 h after stimulation, with 
20 µg of protein loaded per lane. Blots from samples treated with and without BEC were 
incubated together with the same antibody and exposed on the same film. D, Arginase 
activity in mitochondrial and cytosolic fractions from H. pylori-stimulated macrophages, 
assessed at  18 h after activation. Data are the mean ± SEM of two separate experiments. 
*, p < 0.05 comparing the mitochondrial fraction from H. pylori-stimulated cells to the 
cytosolic fraction from unstimulated control cells; §, p < 0.05 comparing the 
mitochondrial fraction to the cytosolic fraction of H. pylori-stimulated cells. E, 
Immunofluorescence photomicrographs of macrophages stained with antibody to mouse 
Arg2 detected with FITC (green); mitochondria were labeled with MitoTracker (red) and 
nuclei were stained with DAPI.
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Effect of arginase inhibition on iNOS protein expression is not observed with another 
enteric pathogen, Citrobacter rodentium
 Because we were able to demonstrate that Arg2 restricts NO production by  an effect 
on iNOS protein levels in H. pylori-stimulated macrophages, we sought  to determine if 
such an effect was specific to H. pylori. In order to address this question, we used the 
mouse colitis-inducing pathogen Citrobacter rodentium, which we have shown induces 
both iNOS and Arg1 in vivo (121). As with H. pylori, C. rodentium lysate stimulated NO 
production in RAW 264.7 cells that was enhanced by BEC (Fig. 5A). In contrast to its 
effect on H. pylori-stimulated cells, addition of BEC did not result in increased iNOS 
protein levels when cells were activated with C. rodentium (Fig. 5B). While H. pylori 
induced only  Arg2 protein expression, C. rodentium stimulation resulted in a modest 
increase in Arg2, and a more significant increase in Arg1 levels. Taken together, these 
data suggest that the mechanisms of inhibition of NO production in macrophages by 
arginase enzymes differs for these pathogens.  
Knockdown of Arg2 increases NO production and iNOS protein levels
 Because H. pylori selectively induces Arg2, we sought to determine if knockdown 
of Arg2 would have the same effect as BEC, which inhibits Arg1 as well as Arg2 (159, 
160). Using transfection of siRNA, we were able to achieve a 65 ± 8.2% knockdown of 
Arg2 in H. pylori-stimulated RAW 264.7 macrophages (Fig. 6A). In cells transfected with 
Arg2 siRNA, we observed significant increases in H. pylori-stimulated NO production 
(Fig. 6B). While knockdown of Arg2 had no effect on H. pylori-stimulated iNOS mRNA 
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FIGURE 5. Arginase inhibition increases NO production, but not iNOS protein levels in 
C. rodentium-stimulated macrophages. RAW 264.7 macrophages were cultured in 
arginine- and serum-free DMEM  with 0.4 mM of L-arginine. A, Cells were stimulated 
with H. pylori or C. rodentium (C. rod) lysates for 24 h in the presence or absence of the 
Arginase Inhibitor BEC (90 µM). NO2– was measured in the supernatant. Data are the 
mean ± SEM  of four separate experiments. **, p < 0.01, ***, p < 0.001 comparing – 
BEC (medium alone) to + BEC in cells treated with the same bacterium. B, Western 
blotting was performed after 24 h for iNOS, Arg2, Arg1, and β-actin, with 20 µg of 
protein loaded per lane. Representative Western blots are shown; similar results were 
observed in two additional experiments. The same membrane was used to assay for all 
protein levels shown. Blots from samples stimulated with H. pylori or C. rodentium were 
incubated together with the same antibody and exposed on the same autoradiograph film.
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levels (Fig. 6C), it resulted in a consistent potentiation of iNOS protein levels by Western 
blot analysis (Fig. 6D), which was confirmed by densitometry (Fig. 6E). 
Arg2-deficient peritoneal macrophages produce more NO and have higher iNOS protein 
levels when stimulated with H. pylori ex vivo
 In order to confirm our findings that Arg2 restricts macrophage NO production, we 
also used primary peritoneal macrophages isolated from WT and Arg2–/– mice. After 6 h 
of culture with H. pylori lysates, mRNA levels of Arg2 were significantly increased in 
cells from WT mice (Fig. 7A), whereas Arg1 levels were not increased (Fig. 7B). iNOS 
mRNA levels were also increased in the peritoneal macrophages from both WT and 
Arg2–/– mice (Fig. 7C). After 24 h of coculture with H. pylori, Arg2-deficient peritoneal 
macrophages produced significantly more NO than WT macrophages (Fig. 7D). Because 
of the limited number of cells, we used flow cytometry for detection of iNOS protein, 
which we have previously demonstrated to be highly sensitive and to correlate well with 
iNOS protein levels assessed by Western blotting in macrophages (13).  There was a 
concomitant increase in iNOS protein levels with H. pylori stimulation in WT cells that 
was further upregulated in Arg2-deficient peritoneal macrophages (Fig. 7D and 7E). 
Inhibition of arginase in H. pylori-stimulated macrophages enhances NO production and 
bacterial killing
 We have reported that iNOS-dependent NO production by  macrophages can kill H. 
pylori and that increased L-arginine availability enhances this effect (93, 113). In the 
current study, we have shown that Arg2 restricts NO production and iNOS translation in 
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FIGURE 6. Knockdown of Arg2 in H. pylori-stimulated macrophages increases NO 
production and iNOS protein expression. RAW 264.7 macrophages were transfected with 
Arg2 siRNA or scrambled control siRNA (Scr) and stimulated with H. pylori lysates at an 
MOI of 100. Experiments were performed at the concentrations of L-arginine shown. A, 
Knockdown of Arg2 in H. pylori-stimulated macrophages cultured in 0.4 mM  of L-
arginine, assessed by  real-time PCR of mRNA expression after 6 h of stimulation. B, 
Effect of knockdown of Arg2 on NO2– production by H. pylori-stimulated macrophages 
measured after 24 h. *, p < 0.05, **, p < 0.01 comparing Arg2 siRNA to the scrambled 
control at the same concentration of L-arginine. Data are the mean ± SEM of two 
separate experiments performed in duplicate. C, iNOS mRNA levels were assessed by 
real-time PCR after 6 h of stimulation. Data were standardized to β-actin and presented as 
fold increase vs. uninfected control at 0.4 mM L-arginine. D, iNOS protein levels were 
assessed by Western blotting after 24 h of stimulation. A representative blot is shown. 
Similar results were observed in two experiments. E, iNOS Western blots were analyzed 
by densitometry and were normalized to β-actin. Data are the mean ± SEM of two 
separate blots. *, p < 0.05 comparing Arg2 siRNA to the scrambled control.
42
&$ 




	



$)) 

(



!




'
 
%
#
 
"
$

%
'
%



"
"

&

#! 




	


!&&

%%%

!







$

"
 


!

"
$
"






#

#! 




	


!%%


!







$

"
 


!

"
$
"






#

  









	

##


""





 


!





( )
 


	





	

 








 
L126),7&

:7
$UJ²²
$UJ²²+3







R
I
0
D[
:7+3
$ % &
'
FIGURE 7. Arg2-deficient peritoneal macrophages produce more NO and express higher 
levels of iNOS protein when stimulated with H. pylori ex vivo. Macrophages were 
isolated from C57BL/6 WT and Arg2–/– mice, counted, and plated. Cells were stimulated 
with H. pylori lysates at an MOI of 100 for 6 h for examination of mRNA levels and 24 h 
for protein levels. A, Arg2, B, Arg1, and C, iNOS mRNA expression by real-time PCR. 
All real-time PCR data were standardized to β-actin and presented as fold increase vs. 
uninfected control at the 0.4 mM concentration of L-arginine. Real-time PCR data are the 
mean ± SEM for four separate experiments. ***, p < 0.001 versus WT Ctrl; §, p < 0.05 
and §§§, p < 0.001 versus WT + HP (panels A and C).  D, NO2– production. Data are the 
mean ± SEM  from two separate experiments each using three mice per group. ***, p < 
0.001 compared to WT control; §§§, p < 0.001 comparing Arg2–/–to WT. E, iNOS protein 
levels were assessed by flow cytometry. Data are the mean ± SEM  of four separate 
experiments. **, p < 0.01 and ***, p < 0.001 compared to WT control; §§, p < 0.01 
comparing Arg2–/– to WT. F, Representative histogram of iNOS protein levels in 
peritoneal macrophages; note the greater shift to the right for the Arg2–/– + HP when 
compared to WT + HP.
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macrophages. Therefore, we sought to determine if inhibiting arginase would enhance 
bacterial killing. For these experiments, we used a transwell system in which H. pylori 
were placed above a filter support to separate the bacteria from the macrophages to 
prevent bacterial killing by phagocytosis. In this model, arginase inhibition also allowed 
macrophages to produce significantly more NO in response to H. pylori (Fig. 8A). In 
parallel, there was enhanced killing of the H. pylori above the filter supports (Fig. 8B). In 
order to determine if the changes in killing with BEC were NO-dependent, we utilized 
cPTIO, an NO scavenger that rapidly  converts NO to NO2 that is then converted to NO2– 
(166). As expected, cPTIO increased the NO2– levels in the macrophage supernatants 
from cells exposed to either H. pylori alone or H. pylori plus BEC. It should be noted that 
we tested cPTIO in a dose range of 50 to 350 µM, and utilized 100 µM  for these studies 
because the effect on NO2– generation plateaued at this concentration. Importantly, 
bacterial killing was significantly reduced in both the H. pylori alone or H. pylori plus 
BEC groups by  the cPTIO (Fig. 8B). These data suggest that the restriction of NO 
production by arginase in response to extracellular H. pylori contributes to the survival of 
this pathogen.
 
In Vivo inhibition of arginase increases NO production and iNOS protein levels in gastric 
macrophages from H. pylori-infected mice
 Because we have reported that Arg2 is increased in H. pylori-infected gastric tissues 
(122), we now determined if arginase inhibits iNOS in vivo. The peak time point of 
macrophage infiltration is 48 h post-inoculation (16). Therefore, we determined the effect 
of BEC (0.1% w/v) administration in the drinking water (121) on levels of iNOS protein 
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FIGURE 8. Arginase inhibition increases macrophage NO production and killing of H. 
pylori that is attenuated with an NO scavenger. Live H. pylori placed above transwell 
filter supports were incubated in 24-well plates with 1 × 106 RAW 264.7 cells in arginine- 
and serum-free DMEM with 0.4 mM of L-arginine for 24 h at an MOI of 100. BEC was 
used at a concentration of 90 µM, and the NO scavenger cPTIO was used at a 
concentration of 100 µM. Bacterial killing was determined by serial dilution and culture 
after 24 h of coculture. A, Effect of arginase inhibition and NO scavenger on NO2– levels. 
**, p < 0.01 for + BEC versus – BEC in the – cPTIO group; #, p < 0.05 for + BEC versus 
– BEC in the + cPTIO group; §§, p < 0.01 for + cPTIO versus – cPTIO in the – BEC 
group; ¶, p < 0.05 for + cPTIO versus – cPTIO in the + BEC group. B, Bacterial killing 
(%) was determined by comparing colony growth from samples cocultured with or 
without macrophages in the presence or absence of BEC and/or cPTIO. *, p < 0.05 for + 
BEC versus – BEC in the – cPTIO group; §, p < 0.05 for + cPTIO versus – cPTIO in the 
– BEC group; ¶¶, p < 0.01 for + cPTIO versus – cPTIO in the + BEC group. Data are the 
mean ± SEM of three separate experiments.
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and NO in gastric macrophages isolated from mice 48 h post-inoculation with H. pylori. 
In mice receiving drinking water alone, there was only  a small increase in NO 
production, but  macrophages from H. pylori-infected mice that were treated with BEC 
exhibited a 2.6 ± 0.5-fold increase in NO production (Fig. 9A). Furthermore, there was a 
significant increase in iNOS protein levels from gastric macrophages isolated from H. 
pylori-infected mice that were treated with BEC (Fig. 9B and 9C). In contrast, iNOS 
mRNA levels were not increased by BEC treatment of mice (data not shown). These data 
show that in vivo inhibition of arginase effectively restores NO production by gastric 
macrophages in response to H. pylori by enhancing iNOS protein synthesis. 
Arginase-mediated effects on NO production and iNOS protein levels in gastric 
macrophages is specifically derived from Arg2 in H. pylori-infected mice
 In order to determine if Arg1 could also play a role in our in vivo model, we 
infected both WT and Arg2–/– mice with H. pylori and determined the effect of BEC 
administration on levels of iNOS protein and NO in isolated gastric macrophages. Similar 
to our previous data (Fig. 9), BEC administration increased NO production (Fig. 10A) 
and iNOS protein levels (Fig. 10B and C) in WT gastric macrophages isolated from 
infected mice. Arg2-deficient  gastric macrophages produced similar levels of NO (Fig. 
10A) and iNOS protein (Fig. 10B and C) as cells from WT mice treated with BEC. 
Importantly, BEC administration to Arg2–/– mice did not further increase NO production 
(Fig. 10A) or iNOS protein levels (Fig. 10B and C) in isolated gastric macrophages. 
These data indicate that Arg1 does not affect gastric macrophage NO production and 
iNOS protein levels during H. pylori infection in vivo.
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FIGURE 9. In Vivo inhibition of arginase increases NO production and iNOS protein 
levels in gastric macrophages. C57BL/6 mice were given a 0.1% BEC solution 
continuously in their drinking water for 24 h before being gavaged with 5 × 108 H. pylori 
bacteria. Treatment with BEC was continued for an additional 48 h and mice were 
sacrificed, followed by isolation of gastric macrophages. A, Cells were plated for 72 h 
and NO2– production was measured in the supernatant. Data are the mean ± SEM of two 
separate experiments, each using three mice per group. **, p < 0.01 comparing HP + 
BEC with Ctrl – BEC. §§, p < 0.01 comparing HP + BEC to HP – BEC. B, iNOS protein 
levels were assessed by flow cytometry  immediately  upon isolation of gastric 
macrophages. Data are the mean ± SEM of three mice per group. **, p < 0.01, ***, p < 
0.001 compared to WT – BEC. §§§, p < 0.01 comparing HP + BEC to HP – BEC. C, 
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Representative histogram of iNOS protein levels in gastric macrophages; note the 
increased shift to the right, indicating higher iNOS levels, in cells from H. pylori-infected 
mice treated with BEC versus water alone.
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FIGURE 10. In Vivo inhibition of arginase does not increase NO production or iNOS 
protein levels in Arg2–/– gastric macrophages from H. pylori-infected mice. C57BL/6 
WT and Arg2–/– mice were given a 0.1% BEC solution continuously  in their drinking 
water for 24 h before being gavaged with 5 × 108 H. pylori bacteria. Treatment with BEC 
was continued for an additional 48 h and mice were sacrificed, followed by isolation of 
gastric macrophages. A, Cells were plated for 72 h and NO2– production was measured in 
the supernatant. Data are the mean ± SEM of three mice per group. ***, p < 0.001 versus 
49
WT – BEC. B, iNOS protein levels were assessed by  flow cytometry immediately upon 
isolation of gastric macrophages. Data are the mean ± SEM of three mice per group. *, p 
< 0.05 versus WT – BEC. C, Representative histogram of iNOS protein levels in gastric 
macrophages; note that the BEC treatment does not shift  the iNOS level in the cells from 
the Arg2–/– mice.
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Discussion
 Nitric oxide production by classically-activated Type I macrophages (M1) is 
required to control a variety of parasitic and bacterial pathogens (167, 168). Microbes can 
avoid NO-dependent killing by suppressing production of NO by the host, through the 
induction of macrophage arginase. For example, downregulation of NO production by 
macrophages has been attributed to induction of Arg1 by  the intracellular parasites 
Leishmania major (125) and Toxoplasma gondii (124), and the intracellular bacterium 
Mycobacterium tuberculosis (124); and to induction of Arg2 by the extracellular parasite 
Trypanosoma brucei brucei (169) and the intracellular bacteria Chlamydia psittaci and C. 
pneumoniae (127).  
 In the current report, we have demonstrated for the first time that upregulation of 
macrophage Arg2 by an extracellular bacterium results in diminished NO-dependent 
killing. We have demonstrated that an inhibitor of macrophage arginase (BEC) enhanced 
NO production and killing of H. pylori, and that these effects are due to enhanced 
translation of iNOS protein, and not to an effect on iNOS mRNA expression levels. The 
effect of BEC occurred in a similar manner at time points tested from 12 to 24 h post-
stimulation, indicating Arg2 has early and consistent suppressive effects on the iNOS 
component of the innate immune response. These findings cannot be attributed to any 
toxic effects of BEC, because macrophage cell viability  testing demonstrated that BEC 
had no deleterious effects on these cells (data not shown). Additionally BEC had no toxic 
effects on H. pylori when tested alone in our killing assay model. We have shown that the 
enhancement of NO production in H. pylori-stimulated cells is specifically attributable to 
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Arg2, because when we employed siRNA knockdown of Arg2 or utilized macrophages 
from Arg2–/– mice we again demonstrated a marked increase in iNOS protein and NO 
production.  We have excluded a role for Arg1, because Arg1 was not induced in RAW 
264.7 cells or peritoneal macrophages with H. pylori stimulation, and treatment of H. 
pylori-infected Arg2–/– mice with a non-selective inhibitor of arginase had no additional 
effect on iNOS or NO levels in gastric macrophages. Additionally, we have reported that 
in contrast to Arg2, Arg1 mRNA levels were not upregulated in mouse or human H. 
pylori gastritis tissues (122). Furthermore, we have found that  there is no compensatory 
upregulation of Arg1 in chronic gastritis tissues from H. pylori infected Arg2–/– mice , as 
we demonstrate in Chapter III of this dissertation (144). An implication of our findings is 
that induction of Arg2 in the host leads to a defective innate immune response manifested 
as diminished iNOS protein translation and NO production by macrophages. Moreover, 
our studies demonstrating that inhibition of macrophage arginase results in enhanced 
iNOS-derived NO production in response to H. pylori in vivo indicate that such a strategy 
could enhance the ability of the immune system to control or eliminate H. pylori 
infection. 
 Arg2 metabolizes L-arginine to produce L-ornithine plus urea. L-ornithine can 
then be metabolized by ODC to produce polyamines. H. pylori possesses urease, which 
metabolizes urea into ammonia that neutralizes hydrochloric acid and facilitates H. pylori 
survival in its acidic niche (170). While H. pylori possesses its own arginase, which acts 
to generate an intracellular supply of urea (96), it  is possible that urea from host arginase 
could be utilized by the bacterium. The importance of this pathway is substantiated by the 
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evidence that H. pylori lacking UreI, the protein responsible for uptake of urea into the 
bacterium, is unable to colonize mice or gerbils (171). Furthermore, host polyamine 
production has been shown to enhance the growth and survival of Leishmania species 
within macrophages (172). It is unknown whether H. pylori utilizes polyamines for 
growth and survival; this is an area of active investigation in our laboratory.
 Arg2 expression could restrict macrophage NO production by competing with 
iNOS for the substrate L-arginine, or by contributing to the production of the polyamine 
spermine. We considered the latter possibility because we have reported that spermine 
inhibits H. pylori-stimulated iNOS translation and NO production in macrophages (93). 
When ODC siRNA was used, which abolishes the increase in spermine synthesis due to 
H. pylori stimulation of macrophages (93), there was an increase in NO production, but 
there was an additional increase in NO generation when this was combined with arginase 
inhibition. If Arg2 were restricting NO production only by enhancing polyamine 
synthesis, then this additive effect of the two inhibitors should not  have occurred. Thus, 
we conclude that there is a combined deleterious effect on innate immunity  by both Arg2 
and ODC each acting to inhibit NO production. Intriguingly, we found that  there was not 
an additive increase in iNOS protein levels when BEC and ODC siRNA were combined, 
despite the potentiation of NO levels. We speculate that while inhibition of ODC and 
arginase each enhances iNOS protein synthesis, combined inhibition of both enzymes 
increases L-arginine substrate availability for iNOS sufficiently  to increase its functional 
activity and cause even more NO production.
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 It has been reported that while iNOS is a cytoplasmic enzyme, Arg2 contains a 
mitochondrial localization domain (173, 174). Our studies demonstrate that Arg2 is 
localized in the mitochondria upon activation by H. pylori. Yet despite this physical 
separation of Arg2 and iNOS, there is competition for the common substrate, intracellular 
L-arginine. These findings suggest that future studies of L-arginine transport by 
mitochondria could prove to be a fruitful area of investigation. Consistent with our 
previous work (113), H. pylori-induced macrophage NO production occurred in a 
concentration-dependent manner. Somewhat surprisingly, in the presence of the Arginase 
Inhibitor BEC, or with knockdown of Arg2, the increase in NO production occurred at  all 
concentrations of L-arginine tested, including at a marked excess of L-arginine. Because 
the circulating level of L-arginine in mammalian serum is approximately 0.1 mM  (114, 
115), which is well above the Km of iNOS (116, 117), one might expect that at  the 
concentrations of 0.4 mM or 1.6 mM, the effect of inhibition of arginase on iNOS-
derived NO production would be lost. Instead, our data suggest that while uptake of 
extracellular L-arginine is required for macrophage NO production (113, 175), the 
competitive effect of arginase is of critical importance in regulating L-arginine 
availability for iNOS, and this consequently affects both iNOS translation and NO 
production in response to H. pylori infection. 
 We demonstrated that inhibition of arginase in vivo enhanced NO production and 
iNOS protein levels in macrophages during acute infection with H. pylori. Due to limited 
availability of the Arginase Inhibitor BEC, we were unable to perform experiments at 
longer time points post-inoculation with H. pylori. It should be noted that we have 
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determined that at 4 months post-inoculation with H. pylori, Arg2–/– mice exhibit a 
correlation between increased gastritis and decreased bacterial colonization that is not 
observed with WT mice, that iNOS expression is increased in the gastric macrophages of 
H. pylori-infected Arg2–/– mice, and that Arg2–/– mice exhibit alterations in T cell 
responses as demonstrated in Chapter III of this dissertation (144).
 There is substantial literature focused on the induction of Arg1 in macrophages, 
resulting in a Type II (M2) phenotype (176, 177), which is characterized by the response 
to Th2 cytokines and parasites, and a lack of iNOS mRNA expression (178). While we 
previously  showed that H. pylori induces Arg2 rather than Arg1 (122), we now 
demonstrate that while Arg2 and iNOS are co-expressed at  the mRNA level, Arg2 acts to 
restrict iNOS translation and hence NO generation. L-arginine is one of the amino acids 
that has been shown to modulate the phosphorylation status of eukaryotic translation 
initiation factor 2α (eIF2α); specifically, the dephosphorylated form enhances translation, 
while the phosphorylated form inhibits it (179, 180). In the case of iNOS, it has been 
suggested that desphosphorylation of eIF2α has a central role in the facilitation of iNOS 
translation in astrocytes (59).  However, we have reported that in H. pylori-stimulated 
macrophages, dephosphorylation of eIF2α occurs with addition of extracellular L-
arginine to L-arginine-starved cells, but there is a further increase in iNOS translation 
with addition of excess L-arginine beyond 0.1 mM, despite no further dephosphorylation 
of eIF2α  (113). These data suggested that additional translational control mechanisms are 
involved. Proteomic studies are in progress in our laboratory to seek additional candidate 
proteins that may  be involved in the regulation of iNOS translation by L-arginine in H. 
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pylori-stimulated macrophages. Based on our data in the current report, additional studies 
related to the effects of altered intracellular availability  of L-arginine on protein 
translation in general and on iNOS translation, specifically, are under development in our 
laboratory. 
 Similar to our results, it has been reported that induction of Arg1 by Th2 
cytokines can result in impaired iNOS translation in macrophages (181). In contrast, we 
found that when the colitis-inducing extracellular pathogen C. rodentium induced Arg1, 
inhibition of arginase resulted in increased NO production without enhancing iNOS 
protein expression. These results suggest that  our findings with H. pylori may  be specific 
in terms of the intracellular competition for L-arginine resulting in an effect on iNOS 
translation. Other pathogens have been shown to induce Arg2 in macrophages, such as 
Trypanosoma brucei brucei (169) and Chlamydia psittaci (127). However, the 
mechanisms underlying effects on NO production have not been elucidated in these 
studies.
 Our data indicate that induction of Arg2 by H. pylori could be a potential 
mechanism by  which the pathogen escapes the host  innate immune response. We 
previously  reported that Arg2, rather than Arg1, is upregulated in H. pylori gastritis 
tissues from human subjects and experimentally infected mice (122). This raises the 
possibility that there could be differences in Arg2 levels or gene polymorphisms in 
human subject groups at varying risk for gastric cancer, the long-term consequence of H. 
pylori infection. Studies related to this issue may be a promising area for future 
investigation. 
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CHAPTER III
IMMUNE EVASION BY HELICOBACTER PYLORI IS MEDIATED BY 
INDUCTION OF MACROPHAGE ARGINASE II
Summary
! Helicobacter pylori infection persists for the life of the host due to the failure of 
the immune response to eradicate the bacterium. Determining how H. pylori escapes the 
immune response in its gastric niche is clinically important. We have demonstrated in 
vitro that macrophage NO production can kill H. pylori, but induction of macrophage 
Arg2 inhibits iNOS translation, causes apoptosis, and restricts bacterial killing. We now 
determined if Arg2 impairs host defense in vivo, using a chronic H. pylori infection 
model. In C57BL/6 mice, expression of Arg2, but not Arg1, was abundant and localized 
to gastric macrophages. Arg2–/– mice had increased histologic gastritis and decreased 
bacterial colonization compared to WT mice. Increased gastritis scores correlated with 
decreased colonization in individual Arg2–/– mice, but not WT mice. When mice infected 
with H. pylori were compared, Arg2–/– mice had more gastric macrophages, more of these 
cells were iNOS+, and these cells expressed higher levels of iNOS protein, as determined 
by flow cytometry  and immunofluorescence microscopy. There was enhanced 
nitrotyrosine staining in infected Arg2–/– versus WT mice, indicating increased NO 
generation. Infected Arg2–/– mice exhibited decreased macrophage apoptosis, as well as 
enhanced IFN-γ, IL-17a, and IL-12p40 expression, and reduced IL-10 levels consistent 
with a more vigorous Th1/Th17 response. These studies demonstrate that  Arg2 
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contributes to the immune evasion of H. pylori by  limiting macrophage iNOS protein 
expression and NO production, mediating macrophage apoptosis, and restraining pro-
inflammatory cytokine responses. 
Introduction
 Helicobacter pylori is a Gram-negative, microaerophilic bacterium that 
selectively colonizes the human stomach. All infected individuals exhibit chronic active 
gastritis and a substantial proportion of subjects develop peptic ulcer disease or gastric 
adenocarcinoma (182). H. pylori infects approximately 50% of the world’s population, 
and, more importantly, the associated gastric cancer is the second leading cause of 
cancer-related death worldwide (82). The infection is usually acquired in childhood and 
persists for the life of the host  despite eliciting a seemingly vigorous immune response 
(36). Understanding the mechanisms by which H. pylori avoids being eliminated by the 
immune system is clinically relevant because antibiotic-based eradication regimens are 
expensive and not always effective, with success rates that can be less than 50% in some 
regions of the world (7). 
 While H. pylori is typically  considered to be noninvasive because most of the 
bacteria reside in the mucus layer of the stomach in contact with the epithelium, studies 
have demonstrated that the bacterium and its products can be in direct contact with 
lamina propria immune cells (49, 50, 148). Consequently, infection with H. pylori results 
in a large influx of immune cells that include neutrophils, macrophages, dendritic cells, 
and lymphocytes, and an associated innate and adaptive immune response (6). While this 
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has been shown to include both Th1 and Th17 components, one hallmark of the response 
is that there is also a downregulation of effective immunity  that appears to involve 
recruitment of Tregs and B cells (36). Vaccination studies, adoptive transfer of Th1-
selected lymphocytes, and efforts to suppress Treg responses have been successful at 
reducing or clearing the infection in mice (31, 32, 183, 184). These studies have provided 
evidence that the cellular immune response is not vigorous enough to lead to eradication 
of the infection. One important aspect that  remains to be fully  elucidated is the role of the 
innate immune response in the impairment of the host response. We propose that there 
may be an inability of effector cells to eliminate the infection when given the opportunity 
to do so. 
 In chapter II of this dissertation and in previous publications, we demonstrated 
that H. pylori induces the expression and activity of iNOS in macrophages both in vivo 
and in vitro (102, 110, 111, 144). Further, we have reported that macrophages cocultured 
with H. pylori can kill the bacterium by an NO-dependent mechanism (113, 144). 
However, this killing is incomplete in vitro, and, moreover, there is clearly a failure of 
this mechanism in vivo despite the expression of iNOS in the infected mucosa (102, 111). 
This reasoning has led our laboratory  to consider the possibility  that iNOS-mediated host 
defense to H. pylori is suboptimal. Importantly, infection of iNOS–/– mice with H. pylori 
results in similar levels of bacterial colonization as wild-type (WT) mice (75), further 
suggesting a defect in iNOS-dependent host defense. 
 In chapter II of this dissertation, we have reported that Arg2, but  not Arg1, is 
upregulated in H. pylori-stimulated macrophages (144). We reported that induction of 
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macrophage Arg2 by H. pylori inhibits iNOS translation, NO production, and bacterial 
killing in vitro (144). Furthermore, in mice infected with H. pylori for 48 h, treatment 
with an arginase inhibitor resulted in increased iNOS protein levels and NO production in 
gastric macrophages (144). We have also reported that the downstream effects of arginase 
metabolism can be detrimental to iNOS-mediated host defense against  H. pylori. The 
polyamine spermine inhibits L-arginine uptake in macrophages, thereby  blocking NO 
production and bacterial killing (93). Moreover, back-conversion of spermine into 
spermidine by  the enzyme spermine oxidase, which is also induced by H. pylori, releases 
hydrogen peroxide that causes apoptosis (137, 185). Consequently, we have found that 
inhibition of arginase blocks H. pylori-induced macrophage apoptosis in our in vitro 
studies (122). 
 We hypothesized that Arg2 expression is detrimental to host defense against H. 
pylori in vivo by restricting macrophage NO production and inducing macrophage 
apoptosis. We now report that chronic infection of Arg2–/– mice with H. pylori results in 
decreased bacterial colonization and increased gastritis as compared to infected WT mice. 
Importantly, we found that  increased gastritis correlated with decreased bacterial 
colonization in individual Arg2–/– mice, but not in WT mice. Moreover, we show that  in 
Arg2–/– mice infected with H. pylori there are more iNOS+ gastric macrophages that 
express increased levels of iNOS, enhanced pro-inflammatory cytokine responses, and 
decreased levels of macrophage apoptosis. Our data suggest that upregulation of 
macrophage Arg2 is detrimental to the host response against H. pylori and demonstrate a 
mechanism by which H. pylori evades host immunity.
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Experimental procedures
 Reagents: All reagents used for RNA extraction were from Invitrogen (Carlsbad, 
CA). Real-time PCR reagents were from Bio-Rad (Hercules, CA). Isolation of DNA was 
performed using the DNeasy® Blood & Tissue kit (QIAGEN, Valencia, CA). All other 
chemicals were from Sigma-Aldrich (St. Louis, MO). 
 Bacteria: H. pylori SS1, a mouse-adapted human strain, was grown on Brucella 
blood agar plates under microaerobic conditions as described (110, 137). Prior to 
infection, bacteria were grown in a Brucella broth culture for 16 – 20 h. Concentrations 
of bacteria were determined by optical density at 600 nm (OD of 1 = 109 CFU/ml) (110). 
 Mice: All animal experiments were approved by the Institutional Animal Care and 
Use Committee at Vanderbilt University  (Nashville, TN). C57BL/6 Arg2–/– and WT male 
mice were used at 6-8 wks of age as described (144). Mice were gavaged with 5 × 108 H. 
pylori SS1 in 100 µl of Brucella broth, or broth vehicle control alone. Some mice were 
sacrificed at 2 d postinoculation, and stomachs were excised and used for isolation of 
gastric macrophages, which was performed as described (102, 113). Other mice were 
sacrificed at 4 mo postinoculation and colonization and gastritis were assessed. H. pylori 
levels were measured by quantitative DNA PCR for H. pylori ureB, standardized to 
mouse 18S rRNA copy number (102). Histologic gastritis was quantified by  a pathologist 
(M.B.P.) using a scale of 0 – 3 for acute inflammation and for chronic inflammation in 
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the regions of the gastric antrum and body with the scores added together for a total score 
of 0 – 12 (102, 186).
 Apoptosis detection by annexin V staining: Gastric macrophages were isolated 
and stained with annexin V conjugated to FITC and 7-aminoactinomycin D (7-AAD; BD 
Biosciences, San Jose, CA) as described (44, 187). 
 Real-time PCR: RNA was extracted using the RNeasy  Mini Kit from Qiagen 
(Valencia, CA). PCR methods were performed as described (113, 121, 122, 144).  Primer 
sequences used were as follows: IL-10, 5′-CCAAGCCTTATCGGAAATGA-3′ (forward) 
a n d 5′- T C A C T C T T C A C C T G C T C C A C - 3′ ( r e v e r s e ) ; I L - 1 2 p 4 0 , 5′-
G A T T C A G A C T C C A G G G G A C A - 3 ′ ( f o r w a r d ) a n d 5 ′ -
C A T C T T C T T C A G G C G T G T C A - 3 ′ ( r e v e r s e ) ; I L - 1 7 a , 5 ′ -
GCTCCAGAAGGCCCTCAGA-3′ (forward) and 5′-CTTTCCCTCCGCATTGACA-3′ 
(reverse); Foxp3, 5′-AGAGCCCTCACAACCAGCTA-3′ (forward) and 5′-
C C A G A T G T T G T G G G T G A G T G - 3 ′ ( r e v e r s e ) ; I L - 6 , 5 ′ -
A G T T G C C T T C T T G G G A C T G A - 3 ′ ( f o r w a r d ) a n d 5 ′ -
T C C A C G AT T T C C C A G A G A A C - 3 ′ ( r e v e r s e ) ; a n d I L - 2 3 p 1 9 , 5 ′-
C A T G G G G C T A T C A G G G A G T A - 3 ′ ( f o r w a r d ) a n d 5 ′ -
AATAATGTGCCCCGTATCCA-3′ (reverse). Primer sequences for IFN-γ (121), Arg1 
(122), Arg2 (144), β-actin (113), and iNOS (113) were as described. 
62
 Immunofluorescence staining for F4/80, Arg2, and iNOS, and immunoperoxidase 
staining for nitrotyrosine and cleaved caspase-3: Immunofluorescence staining for F4/80, 
and DAPI was performed as described (102). iNOS was detected with a rabbit polyclonal 
antibody (1:!00 dilution, BD Biosciences, San Diego, CA). Arg2 was detected with a goat 
polyclonal antibody (1:200 dilution; Santa Cruz Biotechnology, Santa Cruz, CA). 
Immunoperoxidase staining was performed as described (102). Nitrotyrosine was 
detected with a mouse monoclonal anti-vertebrate nitrotyrosine antibody (1:100 dilution; 
Millipore, Billerica, MA). Cleaved caspase-3 was detected with a rabbit polyclonal 
antibody (1:200 dilution; Cell Signaling Technology, Danvers, MA). Quantification of 
cleaved caspase-3 staining was performed by counting all positively-stained cells 
amongst the inflammatory infiltrate and dividing this number by the total number of 
inflammatory cells to calculate the percentage of positive cells. Cell counting was 
performed at 600× magnification under oil immersion.
 Gastric macrophages: Immune cells were isolated from the glandular stomach by 
enzymatic digestion as described (102, 113, 187). Briefly, mice were sacrificed and the 
stomach was removed. The forestomach (nonglandular portion) was excised and 
discarded. The glandular portion of the stomach was washed, cut into 2 mm pieces, and 
digested for 20 min with 1 mg/ml of dispase, 0.25 mg/ml of collagenase A, and 25 U/ml 
DNase (Roche Diagnostics, Indianapolis, IN) at 37°C while shaking.  The suspension 
was passed through a 70 μm cell strainer (BD Biosciences, San Diego, CA) and cells 
harvested by centrifugation. Cells were stained for F4/80 and iNOS and analyzed by flow 
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cytometry. F4/80+ and F4/80+ iNOS+ cell counts were standardized to the weight in 
grams of the glandular stomach.
 Statistical analysis: Quantitative data are shown as the mean ± SE. Statistical 
analysis was performed with Prism version 5.0c (GraphPad Software, Inc., San Diego, 
CA). Where two groups were compared, Student’s t test was used. Data with more than 
two groups were analyzed by ANOVA and the Student-Newman Keuls post-hoc multiple 
comparisons test. p < 0.05 was considered statistically significant. The relationship 
between gastritis and colonization was determined using the Spearman’s correlation test; 
the correlation coefficient, r, is shown along with the p value.
Results
H. pylori infection induces Arg2, not Arg1, in gastric lamina propria F4/80+ 
macrophages 
 Mice were infected for 4 mo, a time point at which we have demonstrated 
consistent development of chronic active gastritis with strain SS1 (102). Arg2 mRNA 
expression was increased by >9–fold in H. pylori-infected WT mice when assessed by 
real-time PCR, while Arg1 was not induced (Fig. 11A and B). Furthermore, Arg1 was not 
upregulated in Arg2–/– mice (Fig. 11B). Additionally, iNOS mRNA expression increased 
in infected WT mice, and this was further enhanced in Arg2–/– mice (Fig. 11C). 
     To determine which cell type expressed Arg2 in the stomach, we immunostained 
formalin-fixed, paraffin-embedded gastric tissue sections from WT and Arg2–/– mice (Fig. 
11D). This staining demonstrated increased Arg2 levels in H. pylori-infected tissues from 
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FIGURE 11. H. pylori infection induces iNOS and Arg2, but not Arg1, in gastric tissues. 
C57BL/6 WT and Arg2–/– mice were infected with H. pylori strain SS1. At 4 mo 
postinfection, mice were sacrificed, gastric tissues were removed, and RNA was 
extracted. iNOS (A), Arg2 (B), and Arg1 (C) mRNA levels were measured by  real-time 
PCR from the antral portion of the stomach. All real-time PCR data were standardized to 
β-actin and presented as fold increase versus uninfected WT mice. Data are the mean ± 
SEM, n = 6 in the uninfected mice and n = 10 in each of the infected mice groups. ***p < 
0.001 compared with WT uninfected mice. §p < 0.05; §§§p < 0.001 compared with WT 
infected mice. D, Photomicrographs, displayed at 200× and 600×, demonstrating Arg2 
immunofluorescence staining in F4/80+ macrophages. F4/80 was detected with 
tetramethyl rhodamine isothiocyanate (red), and Arg2 was detected with FITC. Data are 
representative of 3-4 mice per group.
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WT mice that localized to F4/80+ macrophages. Arg2 staining was not present in 
macrophages in the Arg2–/– tissues.
Chronically-infected Arg2–/– mice have increased gastritis and decreased H. pylori 
colonization
 To determine the role of Arg2 during H. pylori infection, we infected WT and 
Arg2–/– mice for 4 mo and assessed gastritis levels and bacterial colonization. With H. 
pylori infection, there was a significant increase in overall gastritis in WT mice that was 
further increased in the Arg2–/– mice (Fig. 12A). In addition to enhanced gastritis levels, 
we found a significant decrease in H. pylori colonization levels in Arg2–/– mice (Fig. 
12B). Notably, increased gastritis correlated significantly with decreased bacterial 
colonization in Arg2–/– mice (p = 0.006, r = –0.491), but  there was no such effect  in WT 
mice (p = 0.636, r = –0.088). 
 Representative photomicrographs of hematoxylin and eosin-stained gastric 
sections are shown for uninfected and infected WT and Arg2–/– mice (Fig. 12D). These 
demonstrate that in the transition zone between the body and the antrum of the stomach 
where H. pylori-induced inflammation is typically  most severe, there was more extensive 
acute and chronic inflammatory cell infiltration in Arg2–/– mice. There was no 
spontaneous inflammation in the uninfected Arg2–/– mice. Additionally, we observed 
gross thickening of the gastric mucosa in the transition zone of Arg2–/– mice that was 
indicative of increased gastric inflammation (Fig. 12E). 
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FIGURE 12. Increased gastritis and decreased bacterial colonization in Arg2–/– mice. 
C57BL/6 WT and Arg2–/– mice were infected with H. pylori for 4 mo, sacrificed, and 
their stomachs were removed. A, Hematoxylin and eosin-stained slides were prepared 
from a strip of the glandular stomach containing both the antrum and body. Acute and 
chronic inflammation were each scored 0–3 in the antrum and body, and the scores added 
for a 0–12 scale. **p < 0.01. B, DNA was extracted from the body of the stomach and 
bacterial colonization was quantified by real-time PCR for the H. pylori gene ureB 
normalized to 18S rRNA. **p < 0.01. C, Gastritis scores and bacterial colonization were 
plotted for individual WT and Arg2–/– mice to determine if a correlation exists between 
gastritis and bacterial colonization. Linear regression lines are shown. For WT mice, 
Spearman’s correlation coefficient r = –0.088 and p = 0.636. For Arg2–/– mice, 
Spearman’s correlation coefficient r = –0.491 and p = 0.006. D, Representative 
hematoxylin and eosin-stained sections are shown for both uninfected and infected WT 
and Arg2–/– mice. Photomicrographs are depicted at 200× magnification and 600× for the 
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inset. E, Photographs were taken to demonstrate the gross anatomy of the glandular 
portion of the stomach. The red rectangle highlights the transition zone (TZ) of the 
stomach.
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Chronic infection of H. pylori induces pro-inflammatory cytokine production that is 
further enhanced in Arg2–/– mice
 To assess alterations in cytokine production during H. pylori infection and 
determine differences in the immune response, we analyzed mRNA expression of various 
cytokines in uninfected and infected WT and Arg2–/– mice. IFN-γ, IL-12p40, and IL-17a 
were increased in infected WT mice and were further upregulated in Arg2–/– mice (Fig. 
13A, B, and C, respectively). IL-10 expression, a hallmark of the counter-regulatory 
response to Th1 and Th17 responses in H. pylori infection (79, 184), was increased in 
infected WT, but not Arg2–/– mice (Fig. 13D). IL-23p19, IL-6, and Foxp3 were each 
modestly increased upon infection with H. pylori, but  there was no difference between 
the WT and Arg2–/– mice (Fig. 14).
Arg2–/– macrophages are more abundant, express more iNOS, and have increased 
nitrotyrosine staining as compared to WT macrophages during H. pylori infection
 We have previously demonstrated that H. pylori stimulation induces Arg2 
expression in macrophages and this expression attenuates iNOS translation in vitro (144). 
Furthermore, we have shown that Arg2–/– gastric macrophages isolated 48 h 
postinoculation with H. pylori express more iNOS protein and produce more NO as 
compared to WT macrophages (144). Therefore, to determine if such an effect occurred 
during chronic infection with H. pylori, we analyzed levels of the macrophage surface 
marker F4/80, and iNOS protein expression by immunofluorescence in WT and Arg2–/– 
gastric tissues 4 mo postinoculation (Fig. 15), along with the appropriate isotype controls 
(Fig. 16). Consistent with our recent report (102), there was increased macrophage 
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FIGURE 13. Chronic infection with H. pylori induces proinflammatory cytokine 
production that is further enhanced in Arg2–/– mice. mRNA was extracted from the gastric 
antrum of uninfected and infected WT and Arg2–/– mice at 4 mo postinoculation, 
converted to cDNA, and real-time PCR was performed for IFN-γ (A), IL-12p40 (B), 
IL-17a (C), and IL-10 (D). Data were standardized to β-actin and presented as fold 
increase versus uninfected WT mice. *p < 0.05; **p < 0.01; ***p < 0.001 compared to 
uninfected WT mice. §p < 0.05; §§p < 0.01 compared to infected WT mice. For uninfected 
mice, n = 3-6 per group, and for infected mice, n = 5-10 per group.
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FIGURE 14. Chronic infection with H. pylori induces IL-23p19, IL-6, and Foxp3 
expression. mRNA was extracted from the gastric body of uninfected and infected WT 
and Arg2–/– mice at 4 mo postinoculation, converted to cDNA, and real-time PCR was 
performed for IL-23p19 (A), IL-6 (B), and FoxP3 (D). Data were standardized to β-actin 
and presented as fold increase versus uninfected WT mice. *p < 0.05 compared to 
uninfected WT mice. For uninfected mice, n = 3-4 per group, and for infected mice, n = 
5-7 per group.
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staining in H. pylori-infected versus uninfected tissues in WT mice. The abundance of 
this F4/80 staining was significantly  increased in the infected Arg2–/– mice. Similarly, 
with H. pylori infection, iNOS staining was increased in WT mice, but  substantially 
potentiated in the Arg2–/– mice (Fig. 15). When the merged images were assessed, the 
iNOS staining was found to localize predominantly to the F4/80+ cells, and there were 
more iNOS+ macrophages in the Arg2–/– mice (Fig. 15). This staining was present in the 
lamina propria, with trails of iNOS+ macrophages migrating towards the lumen, as well 
as in the submucosal region. 
 To confirm our observation that there are more iNOS+ macrophages in infected 
Arg2–/– mice as compared to infected WT mice, we isolated gastric immune cells and 
analyzed F4/80 and iNOS expression by  flow cytometry. In accordance with our 
immunofluorescence data, we found a significant increase in both the quantity of 
macrophages (Fig. 17A) and iNOS+ macrophages (Fig. 17B) in infected Arg2–/– mice 
compared to WT mice. Representative flow cytometric dot plots are also shown 
demonstrating an increased percentage of F4/80+ iNOS+ cells in infected Arg2–/– mice 
versus WT mice (Fig. 17C). Importantly, the Arg2–/– gastric macrophages expressed more 
iNOS protein than the cells from the WT mice (Fig. 17D and E). 
 Because we found that gastric macrophages isolated from H. pylori-infected 
Arg2–/– mice express higher iNOS protein levels than infected WT mice, we sought to 
determine if this resulted in increased NO production. To assess this, we used 
nitrotyrosine staining as a marker of NO synthesis in the mucosa. Nitrotyrosine formation 
occurs when tyrosine residues react with peroxynitrite, which is formed by the reaction of 
72
) L126 0HUJH
:
7
$
UJ
²
²
:
7

+
3
$
UJ
²
²

+
3
FIGURE 15. Arg2–/– mice have increased iNOS+ macrophages during chronic infection 
with H. pylori. Representative immunofluorescence staining from uninfected and infected 
WT and Arg2–/– mice are shown. The macrophage marker F4/80 was detected with 
tetramethyl rhodamine isothiocyanate (red), iNOS was detected with FITC (green), and 
nuclei were stained with DAPI (blue); co-localization is shown in merged images by  the 
yellow color. Photomicrographs are shown at 200× magnification and 600× for the inset.
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FIGURE 16. Isotype control staining for F4/80 and iNOS during chronic infection with 
H. pylori. Representative immunofluorescent staining from WT and Arg2–/– mice is 
shown. Rat IgG2a was used as an isotype control antibody for F4/80 and was detected 
with tetramethyl rhodamine isothiocyanate (red). Rabbit IgG was used as an isotype 
control antibody for iNOS and was detected with FITC (green). Nuclei were stained with 
′DAPI (blue). Photomicrographs are shown at 200× magnification.
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NO with superoxide (O2–), and this has been used as a marker of the production of 
reactive nitrogen species (158, 188-190). We stained tissues from chronically-infected 
WT and Arg2–/– mice and found that inflammatory cells in Arg2–/– mice had increased 
nitrotyrosine staining as compared to WT mice (Fig. 17F). This staining was most intense 
in mononuclear immune cells of the lamina propria near the luminal surface, similar in 
location to the macrophages that we identified in Fig. 11D and Fig. 15.
H. pylori infection increases macrophage apoptosis that is abolished in Arg2–/– mice
 To determine whether increased survival of macrophages could be a mechanism 
responsible for increased iNOS+ macrophages in Arg2–/– mice, we isolated gastric 
macrophages and measured apoptosis by annexin V staining. We have previously shown 
that H. pylori induces macrophage apoptosis in vitro that is Arg2-dependent (122), 
therefore, we sought to confirm this in vivo.  To pursue this, we used a 48 h model of 
infection, as we have previously demonstrated that there is both maximal macrophage 
infiltration into the stomach, and maximal apoptosis at this timepoint postinoculation 
with H. pylori (187). Additionally, we have demonstrated that  Arg2 restricts NO 
production in gastric macrophages at this timepoint  (113, 144). Consistent with our in 
vitro data, we found that H. pylori infection induced macrophage apoptosis, and that this 
was abolished in Arg2–/– macrophages (Fig. 18A). Representative flow cytometric dot 
plots demonstrating annexin V and 7-AAD staining in infected WT and Arg2–/– 
macrophages are shown in Fig. 18B.
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FIGURE 17. Arg2–/– macrophages are more abundant, express more iNOS, and have 
increased nitrotyrosine staining as compared to WT macrophages during H. pylori 
infection. Gastric cells were isolated from infected WT and Arg2–/– mice and analyzed by 
flow cytometry for the expression of the macrophage marker F4/80 and iNOS. The total 
number of F4/80+ cells (A, **p < 0.01 and ***p < 0.001 vs uninfected WT macrophages; 
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§p < 0.05 vs infected WT macrophages, n = 3 for uninfected groups, and n = 9-10 for 
infected groups) and F4/80+ iNOS+ cells (B, *p < 0.05) are shown.  C, Representative 
flow cytometric dot plots are shown demonstrating iNOS and F4/80 staining in cells 
isolated from infected WT and Arg2–/– mice. D, In the F4/80+ cells, iNOS mean 
fluorescence units (MFU) are shown to demonstrate the level of iNOS expression in 
macrophages. *p < 0.05. E, Representative histogram demonstrating iNOS fluorescence 
in macrophages from uninfected and infected WT and Arg2–/– mice. F, 
Immunoperoxidase staining for nitrotyrosine is shown for uninfected control mice and 
infected WT and Arg2–/– mice at 200× and 600× magnification. Data are representative of 
2 mice in the control group and 4-6 in the infected groups.
77
 We also sought to corroborate this finding in our chronic infection model by 
immunostaining tissues for cleaved caspase-3, a marker for apoptosis in H. pylori 
gastritis tissues (191). In infected WT mice there was abundant staining in the 
mononuclear inflammatory cells with marked staining of cells with apoptotic bodies (Fig. 
18C). In contrast, cleaved caspase-3 staining in Arg2–/– mice was less intense and less 
frequent, which correlates with our findings with the annexin V staining of isolated 
gastric macrophages in Fig. 17A. Additionally, quantification of this staining revealed a 
decrease in cleaved caspase-3 staining among the inflammatory cells in the Arg2–/– mice 
compared to WT mice (Fig. 18D).
Discussion
 H. pylori infection induces a vigorous immune response, and in the murine model 
there is a rapid influx of macrophages (16, 187) and neutrophils (16) 48 h postinfection, 
followed by infiltration of lymphocytes 10 d postinfection (16). This produces a 
smoldering gastritis that persists as long as the bacteria reside in the gastric niche. 
Despite this robust immune response, the bacterium typically persists for the life of the 
host. It is generally assumed that the immune response is not vigorous enough to 
eliminate the infection, due to demonstration of clearance of the bacterium in adoptive 
transfer experiments and IL-10–/– mice, both of which exhibit  enhanced gastric 
inflammation (79, 183). We sought to determine if the macrophage response is inhibited 
by H. pylori. In the current report, we demonstrate that H. pylori upregulates macrophage 
Arg2, thereby restricting iNOS protein levels and NO production, and enhancing 
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FIGURE 18. Arg2–/– macrophages undergo less apoptosis than WT macrophages during 
H. pylori infection. A, Gastric macrophages from WT and Arg2–/– mice were isolated 48 h 
postinoculation with H. pylori SS1 and stained for flow cytometry with annexin V-FITC 
and 7-AAD. The percentage of annexin-V+ 7-AAD– cells are shown. **p < 0.01 
compared to uninfected WT mice. §§p < 0.01 compared to infected WT mice, n = 4 mice 
per group. B, Representative flow cytometric dot plots are shown demonstrating staining 
for annexin V and 7-AAD in gastric macrophages isolated from infected WT and Arg2–/– 
mice. C, Photomicrographs of slides from chronically-infected WT and Arg2–/– mice 
stained for cleaved caspase-3. The arrows are used to highlight apoptotic bodies. Data are 
representative of 7-8 mice per group. D, Quantification of cleaved caspase-3 staining. 
The percentage of positively-stained inflammatory cells is shown.
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macrophage apoptosis. Consequently, this restricts host defense against H. pylori. This is 
the first report to demonstrate that macrophage Arg2 expression has a deleterious impact 
on the effectiveness of host immunity by impairing the inflammatory response in vivo. 
 Herein, we have demonstrated that induction of Arg2 during chronic H. pylori 
infection restricts macrophage iNOS protein levels, limits the pro-inflammatory immune 
response, and increases bacterial colonization. These data confirm our recent studies 
showing that inhibition of macrophage arginase in vitro enhances iNOS translation and 
NO production and, consequently, causes more bacterial killing (144). We have now 
shown that infection with H. pylori causes upregulation of Arg2 that localizes to lamina 
propria and submucosal macrophages. We have previously reported that  Arg2 expression 
is induced in RAW 264.7 cells and peritoneal macrophages stimulated ex vivo with H. 
pylori (122, 144). Furthermore, we have shown that Arg2 gene expression is upregulated 
in human gastric tissues infected with H. pylori (122). Simultaneous induction of both 
iNOS and arginase in macrophages is uncommon, as studies have demonstrated that 
induction of one usually leads to the inhibition of the other (177, 192). Nevertheless, 
several pathogens have devised strategies to upregulate arginase to suppress iNOS-
dependent host defense. For example, downregulation of NO production by macrophages 
has been attributed to induction of Arg1 by  the parasites Leishmania major (125) and 
Toxoplasma gondii (158) and the bacterium Mycobacterium tuberculosis (158); and to 
induction of Arg2 by  the parasite Trypanosoma brucei brucei (128) and the bacteria 
Chlamydia psittaci and Chlamydia pneumoniae (127). We now demonstrate that H. pylori 
upregulates Arg2 in vivo leading to an impaired macrophage immune response.
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 Our data suggest that the enhanced inflammation induced by  H. pylori has no 
benefit for reducing bacterial colonization under normal circumstances. When we 
analyzed the gastritis scores and colonization levels in WT mice, we found that  there was 
no correlation between these two parameters and the linear regression line was almost 
flat. This was surprising because it is generally assumed that in H. pylori infection 
enhanced inflammation will decrease bacterial colonization (31, 79, 183). In fact, 
persistence of the bacterial infection is primarily  thought to be due to an immune 
response that is not vigorous enough (6). However, our data demonstrate that even in WT 
mice with very high levels of gastritis, there was no noticeable ability of this response to 
reduce bacterial colonization. These data suggest that there is a defect  in the immune 
response against H. pylori and that effector mechanisms responsible for clearance of the 
bacterial infection are inhibited. In contrast, mice deficient in Arg2 showed a beneficial 
inverse correlation between gastritis and bacterial colonization, producing a negative 
linear regression line, thus demonstrating that mice with high levels of inflammation had 
less bacterial colonization. These data suggest that Arg2 induction contributes to the 
defective immune response in WT mice. However, in Arg2-deficient mice, the bacterial 
infection was decreased but not eliminated. Linear regression analysis of our Arg2–/– mice 
suggest that after removal of the Arg2 ‘block’, the effectiveness of the immune response 
is restored, but enhancement of other responses may be needed to completely eliminate 
the infection, which correlates with what others have demonstrated with lymphocyte 
adoptive transfer experiments (24, 183). 
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 We previously demonstrated that Arg2 localizes to mitochondria while iNOS 
resides in the cytoplasm (144). Although these two enzymes are physically  separated, 
Arg2 is still able to restrict NO production by its inhibitory effect on iNOS translation; as 
such, NO production in response to H. pylori can be enhanced in vitro in macrophages by 
inhibition of arginase activity, knockdown of Arg2, or use of Arg2–/– cells (144). These 
previous findings are substantiated by our current in vivo data that gastric macrophages 
isolated from H. pylori-infected Arg2–/– mice express more iNOS protein than WT 
macrophages. We also demonstrated enhanced nitrotyrosine staining in these cells which 
is a signature of increased NO production. Our data indicate that the competition for 
intracellular L-arginine is important for modulating host immunity against H. pylori. 
 It has been reported that Arg2–/– mice have higher levels of serum L-arginine than 
WT mice under basal conditions (114). Such an effect  could enhance T cell responses 
because it has been reported that T cell responses in vitro are inhibited under conditions 
of limited L-arginine availability (193). Furthermore, it  has been shown that Arg1-
expressing macrophages can inhibit  both the re-expression of T cell receptors and T cell 
proliferation in vitro (98, 194) and T cell proliferation in vivo (47). We have considered 
the possibility that the effects we have described with our Arg2–/– mice may have been 
due to enhanced T cell responses that could ensue from increased L-arginine availability. 
However, when we supplemented WT mice with L-arginine in their drinking water, we 
found no reduction in H. pylori colonization when assessed at 4 mo postinoculation (data 
not shown). This lack of effect of L-arginine treatment may be due to the presence of 
Arg2, which impairs NO-dependent  antimicrobial host defense. Our data suggest 
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impairment of classical (M1) activation (176) of macrophages in H. pylori infection. 
However, the competing alternative (M2) activation nomenclature has been used to refer 
to cells with induction of Arg1 rather than Arg2 (176). We have shown that upregulation 
of Arg1 does not occur in H. pylori infection, and intriguingly, Arg2 induction has 
recently  been associated with M1 responses in a murine model of atherosclerosis (195). 
Another factor in the utilization of L-arginine in host defense is that its uptake into 
macrophages is required to allow generation of NO (113, 196). We have reported that 
while the L-arginine transporter, cationic amino acid transporter 2, is upregulated in 
gastric macrophages upon infection with H. pylori, L-arginine uptake is actually inhibited 
by the polyamine spermine, which is generated downstream of Arg2 (102). We are 
currently investigating the role of macrophage cationic amino acid transporter 2 during 
chronic H. pylori infection. 
 Additionally, we have found that induction of Arg2 enhances H. pylori-induced 
apoptosis in gastric macrophages, consistent with our previous in vitro findings (122). 
This apoptosis was associated with decreased abundance of macrophages in the gastric 
mucosa in WT mice when compared to Arg2–/– mice. Another contributing factor to the 
increase in macrophages in the Arg2–/– mice may be increased stimulation of 
mononuclear cell infiltration, since enhanced Th1 and Th17 responses, as we have 
detected, have been correlated with increased inflammatory cells in the gastric mucosa 
(31, 79, 183). Taken together, our data suggest that  the limited numbers of macrophages 
associated with Arg2 induction results in diminished gastric inflammation and pro-
inflammatory cytokine production. Consequently, the inhibition of H. pylori-induced 
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macrophage apoptosis that we achieved by using mice deficient in Arg2 caused an 
increase in the number of surviving infiltrating macrophages, and an associated increase 
in gross and histologic gastritis (increased neutrophils and lymphocytes), and 
proinflammatory cytokine production. Other reports have demonstrated that macrophages 
mediate gastric inflammation during H. pylori infection, since depletion of macrophages 
from mice with clodronate-loaded liposomes resulted in reduced levels of histologic 
gastritis (197). It  should be noted that the reduction in macrophages had no effect on H. 
pylori colonization levels in that study (197), which is consistent with our current 
findings that WT mice with higher gastritis scores exhibited no reduction in colonization, 
and further supports the concept that altered macrophage immune function is a hallmark 
of H. pylori infection, since loss of cells would not  be expected to have an effect on host 
defense if the cells are already defective. 
 In summary, our data indicate that  induction of Arg2 by  H. pylori is a mechanism 
by which the pathogen escapes the host  innate immune response and contributes to the 
immunopathogenesis of the infection. However, we also recognize that another 
possibility is that the Arg2 component of the innate immune response in macrophages 
may serve to protect the host  from unrestrained inflammation, and as such Arg2 could 
prevent overabundant  nitrosative stress and its associated mutagenic potential that would 
derive from unrestricted NO production (198). However, it should be noted that the 
increased nitrotyrosine staining in the Arg2–/– mice that we observed did not appear to 
involve epithelial cells in our model, indicating that Arg2 may be dispensable in 
protecting epithelial cells from nitrosative stress. Because we have reported that Arg2 is 
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upregulated in H. pylori gastritis tissues from human subjects, insights into the 
importance of Arg2 could be gained from molecular epidemiology studies of Arg2 levels 
in human subject groups, such as in persons from Latin America where regions of low 
versus high risk of gastric cancer have been described, despite similarly high prevalence 
rates of H. pylori (145-147). Studies related to this issue may  be a promising area for 
future investigation.
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CHAPTER IV
CONCLUSION
Summary
 H. pylori is an important human pathogen and research to determine the failure of 
the immune response during this infection is clinically  important. This has been the focus 
of our laboratory  and my dissertation in particular.  In this dissertation, I have presented 
research demonstrating our discovery  of a mechanism by which H. pylori escapes the 
host immune response. By  upregulating Arg2, H. pylori effectively reduces NO 
production and induces apoptosis in macrophages. We have previously  demonstrated that 
Arg2 is upregulated in humans infected with H. pylori. Consequently, an important next 
step for this project  is to determine if the mechanisms we have demonstrated herein are 
occurring in humans. This could potentially be a promising area for future investigation.
  In Chapter II, we examined the importance of H. pylori-induced expression of 
macrophage Arg2 in vitro and determined its effects on iNOS activity. We demonstrated 
for the first time that upregulation of macrophage Arg2 by  an extracellular bacterium 
results in diminished NO-dependent killing. We have demonstrated that an inhibitor of 
macrophage arginase (BEC) enhanced NO production and killing of H. pylori, and that 
these effects are due to enhanced translation of iNOS protein, and not to an effect on 
iNOS mRNA expression levels. The effect of BEC occurred in a similar manner at  time 
points tested from 12 to 24 h post-stimulation, indicating Arg2 has early and consistent 
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suppressive effects on the iNOS component of the innate immune response. We have 
shown that the enhancement of NO production in H. pylori-stimulated cells is specifically 
attributable to Arg2, because when we employed siRNA knockdown of Arg2 or utilized 
macrophages from Arg2–/– mice we again demonstrated a marked increase in iNOS 
protein and NO production.  An implication of our findings is that induction of Arg2 in 
the host leads to a defective innate immune response manifested as diminished iNOS 
protein translation and NO production by macrophages. Moreover, our studies 
demonstrating that inhibition of macrophage arginase results in enhanced iNOS-derived 
NO production in response to H. pylori in vivo indicate that such a strategy could enhance 
the ability of the immune system to control or eliminate H. pylori infection.
  In Chapter III, we examined the importance of H. pylori-induced expression of 
Arg2 in vivo. We demonstrated that H. pylori upregulates Arg2 in the gastric mucosa that 
localizes to F4/80+ macrophages, thereby restricting iNOS protein levels and NO 
production, and enhancing macrophage apoptosis. Consequently, this restricts host 
defense against H. pylori. This is the first report to demonstrate that macrophage Arg2 
expression has a deleterious impact on the effectiveness of host immunity by impairing 
the inflammatory response in vivo. These data confirm our recent studies presented in 
chapter II of this dissertation showing that inhibition of macrophage arginase in vitro 
enhances iNOS translation and NO production and, consequently, causes more bacterial 
killing (144). Our data suggest that the enhanced inflammation induced by  H. pylori has 
no benefit  for reducing bacterial colonization under normal circumstances. When we 
analyzed the gastritis scores and colonization levels in WT mice, we found that  there was 
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no correlation between these two parameters and the linear regression line was almost 
flat. These data suggest that there is a defect in the immune response against H. pylori 
and that effector mechanisms responsible for clearance of the bacterial infection are 
inhibited. In contrast, mice deficient in Arg2 showed a beneficial inverse correlation 
between gastritis and bacterial colonization, producing a negative linear regression line, 
thus demonstrating that mice with high levels of inflammation had less bacterial 
colonization. These data suggest that Arg2 induction contributes to the defective immune 
response in WT mice. 
  In summary, we have demonstrated that induction of Arg2 by  H. pylori is 
detrimental to the macrophage response against the infection. We have demonstrated that 
induction of Arg2 by H. pylori causes decreased iNOS translation, decreased NO 
production, decreased bacterial killing, and enhanced macrophage apoptosis. The effects 
of Arg2 induction in macrophages is demonstrated in Fig. 19. Therefore, induction of 
macrophage Arg2 restricts host defense against H. pylori and contributes to the immune 
evasion of H. pylori. 
Future directions
Determine the H. pylori factor responsible for upregulation of Arg2
  We have demonstrated that H. pylori induces Arg2 expression in macrophages and 
this contributes to the defective immune response against H. pylori. One important  aspect 
surrounding this project that has yet to be identified is the H. pylori factor (e.g. protein(s) 
or other components such as lipids) responsible for upregulating Arg2. Our data indicates 
that this product may be secreted, as experiments conducted in which H. pylori was
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FIGURE 19. Working model demonstrating the consequences of Arg2 induction. This 
figure summarizes the main findings of this dissertation and shows how the results of 
Arg2 induction contribute to human disease induced by H. pylori. 
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 suspended over a transwell and macrophages were cultured underneath still allow for 
induction of Arg2 after 6 hr. Consequently, inhibition of arginase using this transwell 
system leads to increased NO production and bacterial killing. In order to determine if 
there is a protein responsible for upregulation of Arg2, we began testing different 
isogenic mutant strains of H. pylori 7.13.   Our goal was to discover a mutant strain of H. 
pylori that would not induce Arg2, thereby providing a clue as to which protein may be 
responsible for the induction of Arg2. The mutants we tested were cagA, cagM, cagE, 
vacA, oipA, slt, and ureA. Each of these mutant strains are viable, although some exhibit 
slower growth on blood agar plates. We used these mutants to activate the macrophage 
RAW264.7 cell line, with or without a transwell and measured Arg2 mRNA expression 
by real-time PCR.  At the time of writing this dissertation, these preliminary experiments 
have not revealed any  mutants that do not induce Arg2. Another method of identifying an 
H. pylori protein responsible for induction of Arg2 is to grow a broth culture of H. pylori 
and fractionate the supernatant. One could then stimulate macrophages using each one of 
these fractions and determine which fraction induces Arg2 expression. After identifying 
the fraction capable of inducing Arg2, mass spectrometry  could be used to identify the 
various proteins within that fraction. This could be followed by further experiments to 
test each protein individually to determine if it possesses the activity  necessary  to induce 
Arg2. 
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Determine the signaling pathway leading to induction of Arg2
  Another additional aspect of this project that  has yet to be resolved is to identify 
which intracellular signaling pathway  is responsible for induction of Arg2. We planned to 
address this question by activating RAW 264.7 cells with H. pylori in the presence of 
various signaling pathway  inhibitors. Our goal was to find an inhibitor that would block 
the induction of Arg2 by H. pylori. This would provide evidence that induction of Arg2 is 
dependent upon the identified pathway. We planned to inhibit several pathways by using 
various inhibitors including: NFκB inhibitor (Bay  11-7082), MEK inhibitor (PD98059), 
ERK 1/2 inhibitor [ERKi (3-(2-aminoethyl)-5-((4-ethoxyphenyl)methylene)-2,4-
thiazolidinedione, HCl], JNK inhibitor (SP600125), p38 inhibitor (SB203580), PI3K 
inhibitor (LY294002), Src inhibitor (PP1), and the HIF-1 inhibitor [HIFi (3-(2-(4-
adamantan-1-yl-phenoxy)-acetylamino)-4-hydroxybenzoic acid methyl ester]. These 
inhibitors cover a broad range of signaling pathways, one of which should play  a role in 
H. pylori-induced Arg2 upregulation. This is closely related to the future direction above 
to identify the H. pylori factor responsible for induction of Arg2, and it could possibly 
help  to narrow down the list of targets that may possess this ability  to induce Arg2. By 
identifying the signaling pathway that is responsible for induction of Arg2, one could 
then determine which receptor senses H. pylori and leads to Arg2 induction. It is possible 
that TLRs may play a role in induction of Arg2. Several TLRs have now been identified 
along with their respective ligands. Importantly, however, many TLRs can bind multiple 
targets. The importance of TLRs for induction of macrophage Arg2 can be determined 
using macrophages isolated from myeloid differentiation primary response gene (88) 
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(MyD88)-deficient mice. MyD88 is a universal adaptor protein that is used by  all TLRs, 
except TLR3, to activate the transcription factor NFκB. If a certain TLR was found to be 
involved, this would potentially narrow down the list  of targets to those TLR ligands. 
However, there is a chance that the protein has not been previously identified to bind that 
specific TLR. 
Determine the mechanism by which L-arginine affects iNOS translation
  An interesting finding in our studies concerning the role of Arg2 in H. pylori 
infection was that inhibition of arginase, selective knockdown of Arg2, and genetic 
knockout of Arg2 all resulted in enhanced iNOS protein levels without effecting iNOS 
mRNA levels. Using RAW 264.7 cells, we demonstrated that this increase in iNOS 
protein expression was due to enhanced iNOS translation. We have previously 
demonstrated that exogenous addition of the iNOS and arginase substrate, L-arginine, to 
the medium of H. pylori-stimulated macrophages also caused an increase in iNOS 
translation. Consequently, we believe that the increase in iNOS translation that we see 
upon inhibition of Arg2 is due to increased levels of intracellular L-arginine. By blocking 
arginase activity, there should be more L-arginine inside the cell for iNOS. In our first 
paper describing that addition of L-arginine to H. pylori-stimulated macrophages 
enhances iNOS translation, we demonstrated that the enhancement of iNOS protein levels 
was due to enhanced translation and not due to increased stability of iNOS protein. 
Furthermore, we demonstrated that the increases we saw in iNOS protein levels upon 
addition of L-arginine were specific to iNOS and did not enhance global translation. 
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Moreover, only L-arginine was found to cause this effect, not the addition of other amino 
acids. We attempted to determine the mechanism by which addition of L-arginine 
enhances iNOS translation by examining eIF2α. It has been shown that different levels of 
amino acids, including L-arginine, can alter the phosphorylation status of eIF2α. The 
dephosphorylated form enhances translation, whereas the phosphorylated form is 
considered to be a global inhibitor of protein translation. Dephosphorylation of eIF2α has 
been associated with facilitation of iNOS translation in brain astrocytes (31), but this 
phenomenon had not been previously studied in immune cells or in cells exposed to an 
infectious stimulus. We therefore assessed levels of the eIF2α phosphoprotein and found 
that the levels were high in unstimulated cells even in the presence of high levels of L-
arginine, indicating that L-arginine alone is unlikely to be sufficient to activate protein 
translation in macrophages. In cells activated with H. pylori, phospho-eIF2α levels 
rapidly decreased as L-arginine levels were increased from 0 to 0.1 mM, but there was 
not a significant change at higher concentrations of L-arginine. These data were 
consistent with the increase in global protein translation at 0.1 mM L-arginine that did 
not increase further at higher concentrations of L-arginine that we observed. However, 
these results were not consistent with the continued increase in iNOS protein expression 
and iNOS protein translation with concentrations of L-arginine above 0.1 mM, indicating 
that eIF2α is not responsible for enhanced iNOS translation. Proteomic experiments are 
currently being performed in order to determine potential proteins that may regulate 
iNOS translation.
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Final remarks
  It is truly amazing that H. pylori has infected 50% of the total human population 
for the past 50,000 years, caused gastritis in 100% of those infected, caused peptic ulcers 
in approximately 10%, and initiated the pathogenic environment leading to gastric 
adenocarcinoma or MALT lymphoma in approximately  1%. Given these numbers we can 
estimate that there are approximately  3.45 billion people infected with H. pylori in the 
world. That is a lot of stomach aches. Additionally, we can estimate that 345 million 
people have H. pylori-induced peptic ulcers and 34.5 million people have gastric cancer. 
The detrimental effects of this pathogen are astronomical, and only  recently  has it 
become known that these diseases are caused by H. pylori. We know that the infection 
can potentially be cured with antibiotics and that diseases can be prevented, but is it 
feasible to treat half of the world with antibiotics? Methicillin-resistant Staphylococcus 
aureus (MRSA) is causing high rates of morbidity and mortality because of its resistance 
to certain antibiotics. Prescribing half of the world antibiotics would possibly cause an 
increase in antibiotic resistance of pathogenic bacteria, including H. pylori, as has been 
previously  reported (7). Although some may argue that infection with H. pylori may 
provide a selective advantage due to the long period of co-evolution with humans, the 
massive detriment to human health caused by this bacterium cannot be overlooked. The 
discovery  of this bacterium, along with its role in causing disease, has provided scientists 
with a starting point to learn effective mechanisms to alleviate this disease burden. My 
dissertation project  is relevant to this because I have sought to determine the mechanisms 
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responsible for the persistent colonization of H. pylori and how altering the immune 
response may contribute to clearance of the infection. 
  The immune system is ineffective at resolving an H. pylori infection. The reason 
for this ineffectiveness of the immune response is one of the most important topics of this 
field. Moreover, the results found by studying the immune response against H. pylori can 
be applied to other chronic infections and the immune system in general. Using H. pylori 
as a model, scientists have learned a great  deal on how a chronic immune response is 
detrimental for humans and this may contribute to gastric cancer. It is difficult  for me to 
conceive that the immune system cannot eliminate this infection. The immune system has 
been responsible for protecting the human race against pathogens for many years. It is 
possible that  the immune system does eliminate the infection in some individuals, 
although this is difficult to determine. It may be that in some parts of the world, due to 
the high prevalence of the bacterium, some individuals may eliminate the infection only 
to be reinfected later on in life. Because H. pylori usually causes mild clinical symptoms, 
and most infected persons live a full life, there may be less selective pressure upon the 
immune system to eliminate the infection. 
  My project has sought to determine possible mechanisms by which the immune 
system is unable to eliminate the infection. We have discovered a potential mechanism by 
which H. pylori is able to evade the immune response and persist  for the life of the host. I 
have demonstrated in the past two chapters that H. pylori induces Arg2 in macrophages. 
Induction of Arg2 inhibits the macrophage response by blocking iNOS translation. 
Furthermore, L-arginine metabolism by  Arg2 contributes to the production of spermine, 
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which is necessary for H. pylori-induced apoptosis. By upregulating Arg2, H. pylori is 
able to decrease the production of reactive oxygen and nitrogen species that can kill it. 
Furthermore, it  causes the death of macrophages which are capable of killing H. pylori 
utilizing several different mechanisms. The most interesting result that I found was that in 
WT mice, increased gastric inflammation had no effect on bacterial colonization, but in 
mice deficient in Arg2, increased gastric inflammation correlated with decreased bacterial 
colonization. This data suggests that Arg2 blocks effective immunity. We have 
demonstrated that Arg2 is also upregulated in the stomach of humans infected with H. 
pylori. It will be interesting to determine if Arg2 restricts iNOS-dependent host defense 
and causes macrophage apoptosis in humans. 
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